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ABSTRACT 
The large conformational changes observed by Molecular Dynamics simulation studies on the 
product release in the LID and shikimic acid binding (SB) domains of the shikimate kinase (SK) 
enzyme have been exploited in the development of reversible competitive inhibitors against SK from 
M. tuberculosis and H. pylori. This enzyme is is a recognized target for antibiotic drug discovery. 
The reported C5-substituted shikimic acid analogs interact with the dynamic apolar pocket that 
surrounds the C4 and C5 hydroxyl groups of the natural substrate, cause the opening of the LID and 
SB domains, and capture the essential arginine far from the ATP binding site as required for 
catalysis. The 3-nitrobenzyl 3e and 5-benzothiophenyl derivatives 3i proved to be the most potent 
inhibitors. An ester prodrug of 3i was the most efficient derivative in achieving good in vitro activity 
against H. pylori, having a MIC value of 4 µg/mL. 
  
INTRODUCTION 
Antibiotics are probably the most successful drugs to be developed in the history of Medicine.
1 
The 
discovery of penicillin in 1928 and the wide therapeutic arsenal developed thereafter have saved the 
lives of millions of people. Unfortunately, this enormous success was soon accompanied by the ever 
increasing emergence of drug resistance in bacteria, a problem that has become one of the most 
important public health issues of the early 21st century.
2–7
 In a recent study it was demostrated that 
antibiotic resistance is a natural phenomenon that predates the golden age of antibiotic therapy, but 
the inappropriate and excessive use of these drugs in medicine, veterinary medicine and agriculture 
over the years has caused the antibiotic resistance problem to reach current levels.
8
 It is therefore an 
urgent matter to develop novel and alternative therapies, to identify unexplored bacterial targets and 
to gain a detailed knowledge of the mechanism of action and binding determinants of those targets in 
order to develop effective inhibitors. 
One of the most successful strategies to combat bacterial infections is based on the disruption of 
essential bacterial processes. However, most of the antibiotics in clinical use target a very small 
number of key bacterial functions and resistance to them is widespread and well known. Therefore, 
the search for unexplored bacterial functions appears to be a good option for the development of 
novel antimicrobial agents with a new mechanism of action. In this context, in recent years a great 
deal of attention has been devoted to the inhibition of the enzymes involved in the shikimic acid 
pathway, in which chorismic acid is synthesized.
9,10
 This compound is the precursor of aromatic 
amino acids and other metabolites, including folates, ubiquinone and vitamins E and K. The fact that 
the enzymes involved in this pathway are essential in certain important microorganisms but absent in 
mammals makes them attractive targets for the development of antimicrobial agents.
11
 Our recent 
work has focused on the development of inhibitors that target the fifth enzyme of the shikimic acid 
pathway, namely shikimate kinase (SK, EC 2.7.1.71, aroK gene).
9
 SK is considered to be an 
attractive target for relevant pathogenic bacteria such as Mycobacterium tuberculosis, which is 
responsible for tuberculosis, Helicobacter pylori, which is the causative agent of gastric and 
duodenal ulcers and has also been classified as a type I carcinogen, and Pseudomonas aeruginosa, 
which is one of the most common pathogens in healthcare-associated infections and represents 13% 
of multidrug-resistant strains to nearly all antibiotics. This enzyme is also essential in Acinetobacter 
baylyi, Escherichia coli, Haemophilus influenza, Campylobacter jejuni and Francisella novicida.
12
 
SK would therefore be an attractive target for the development of new drugs against several 
important bacterial diseases. Diverse compounds that target the SK enzyme have been discovered by 
screening (Figure 1). For example, Simithy et al.
13
 used LC-MS and a library of about 400 
antimycobacterial compounds, to identify several compounds with IC50 values in the micromolar 
range that inhibit SK from M. tuberculosis (Mt-SK). Moreover, Han et al.
14
 discovered by high-
throughput screening of a library of about 3000 compounds two inhibitors of SK from Helicobacter 
pylori (Hp-SK) with IC50 values also in the micromolar range. 
SK catalyzes the stereospecific phosphorylation of the C3 hydroxyl group of shikimic acid (1) by 
transferring the γ-phosphate group of ATP to the hydroxyl group to provide shikimate 3-phosphate 
(2) and ADP (Scheme 1). NMR and computational studies have shown that the reaction catalyzed by 
SK involves a dissociative phosphoryl-transfer mechanism, in which a trigonal metaphosphate 
intermediate is formed first by cleavage of the γ OP bond in ATP, followed by subsequent 
nucleophilic attack of the C3 hydroxyl group.
15
 It was suggested that the rate-limiting step of the 
reaction would be the nucleophilic attack by the C3 hydroxyl group to the metaphosphate 
intermediate to afford a tetrahedral transition state. Moreover, based on the results of structural 
studies it was suggested that Asp33/Asp34 (in H. pylori and M. tuberculosis, respectively) would act 
as a general base to deprotonate the C3 hydroxyl group in 1 for nucleophilic attack.
16
 SK is a 
magnesium-dependent enzyme that has two recognition centers, i.e., one for shikimic acid (1) and 
another for the cofactor (ATP), with different key interactions in both cases. SK has three domains: 
(1) the CORE domain that contains five stranded parallel -sheets and the P-loop, which forms the 
binding site for ATP and ADP; (2) the LID domain, which closes over the active site and has 
residues that are essential for the binding of ATP and catalysis; and (3) the substrate binding (SB) 
domain, which is responsible for the recognition and binding of 1 (Figure S1). The SK enzyme is 
amazingly designed to recognize an unstable conformation for a cyclohexene ring with two of the 
three hydroxyl groups in an axial arrangement. By forcing the diaxial disposition of the C4 and C5 
hydroxyl groups, the enzyme controls the equatorial disposition of the C3 hydroxyl group and allows 
its selective phosphorylation. The available crystal structures show that shikimic acid (1) is anchored 
to the active site (SB domain) by a salt bridge with a conserved arginine (Arg132/Arg136 in H. 
pylori and M. tuberculosis, respectively), a double hydrogen bond between the side chain of a 
conserved aspartate (Asp33/Asp34 in H. pylori and M. tuberculosis, respectively) and the C3 and C4 
hydroxyl groups, and a hydrogen bond between the C3 hydroxyl group and the NH main chain 
amide of a conserved glycine (Gly81/Gly80 in H. pylori and M. tuberculosis, respectively).
16,17
 In 
addition, the C4 hydroxyl group is also fixed in an axial arrangement by hydrogen bonding with a 
structural water molecule (WAT1), the position of which is frozen by three conserved residues 
(Glu60/Glu61, Arg57/Arg58 and Gly81/Gly80 in H. pylori and M. tuberculosis, respectively). The 
axial disposition of the C5 hydroxyl group is controlled by two water molecules that interact by 
hydrogen bonding with the residues located in the LID. The substrate is surrounded by an apolar 
pocket generated by several lipophilic residues located in -helices 2, 3 and 5 (SB domain) in 
such a way that it is isolated from the solvent environment. 
Structural and Molecular Dynamics (MD) simulation studies also revealed that there are three key 
structural factors for catalysis:
18
 (1) a closed form of the LID domain that allows the appropriate 
disposition of ATP in the active site, which is controlled by a cation-π interaction with 
Arg107/Arg110, and the activation of the γ-phosphate of ATP by the guanidinium group of the 
essential arginine Arg116/Arg117 (H. pylori and M. tuberculosis, respectively); (2) a closed form of 
the SB domain in order to bring the substrates together for the phosphoryl-transfer reaction and to 
isolate the substrate within an apolar cavity; and (3) a flexible LID and SB domain for product 
release, which is triggered by the essential arginine.
18
  
Reasoning that closed forms of the LID and SB domains are required for catalysis, we decided to 
explore the possible inhibition of the SK enzyme by blocking the appropriate closed form of those 
domains. To this end, we report here the synthesis and inhibitory properties against Mt-SK and Hp-
SK of several shikimic acid analogs, namely compounds 3–6, that incorporate diverse aromatic 
moieties at the C5 hydroxyl group of shikimic acid (1) (Figure 2). The design of the reported 
inhibitors was based on: (1) the dynamic behavior of the SB and LID domains observed during 
product release by MD simulations studies; (2) the role and the type of residues located in the SB 
domain in order to achieve the interaction with this `dynamic apolar´ pocket; and (3) the crystal 
structure of E114A Hp-SK variant enzyme in complex with the naphthalene derivative 7 (PDB entry 
3N2E, 2.53 Å) described by Cheng et al.
19
 (Figure 3). This structure reveals that this aromatic ligand, 
which has an IC50 value of 4.9 µM against Hp-SK, prevents closure of the active site for catalysis by 
causing a large conformational change in the LID domain with the subsequent inappropriate 
disposition of the essential arginine. The shikimic acid derivatives described here incorporate diverse 
O-benzyl groups (compounds 3), and 1,2,3-triazole groups (compounds 4–5). In addition, 
considering that (3S)-3-aminoshikimic acid
18
 proved to be a competitive reversible inhibitor of Mt-
SK with a Ki of 65 µM, we also studied the effect of replacing the C3 hydroxyl group in the O-
benzyl derivatives 3 by an amino group, namely compounds 6. The binding modes of the reported 
compounds with the two SK enzymes were initially studied using GOLD 5.2
20
 and then further 
analyzed by MD simulation studies. The results of inhibition studies, along with the computational 
data, allowed us to understand the binding differences between the two enzymes. These studies also 
reveal that the intrinsic motion of an enzyme is a key point to be considered in inhibitor design. 
RESULTS AND DISCUSSION 
In order to be selective for this kinase, and considering that the binding site for ATP and ADP, which 
contains the consensus sequence GXXXXGKT/S (with X being any residue), is rather conserved in 
many ATP- or GTP-binding proteins, we focused on the design of compounds that bind to the SB 
binding site. The starting point for the design of the reported compounds was the study of the 
structural changes required in the SB and LID binding domains for the release of shikimate-3-
phosphate (2) from the active site. This study was carried out by analyzing the dynamic behavior of 
the SK/ADP/2 complex and the results are discussed below. 
Dynamic Behavior of SK Enzymes: Molecular Dynamics Simulation Studies – For the Mt-SK 
enzyme, we have shown previously that an opening of up to 10 Å of the SB domain and of up to 8 Å 
of the LID domain are required for product release (Figure 4).
18
 Overall, Mt-SK undergoes opening 
of the SB and LID domains in a similar way to the movement of an accordion, which is surprising 
given that the SB domain is composed of three -helices 2, 3 and 5. This opening allows a rapid 
conformational change of the product to its thermodynamically favorable conformation, i.e., with the 
C4 and C5 hydroxyl groups in a pseudo-equatorial disposition. This process is mainly carried out by 
three conserved arginines, specifically Arg117, Arg136, and Arg58. The essential arginine triggers 
the process by pulling on the phosphate group of the product, which in turn breaks the key 
interactions with the active site.  
In order to evaluate the possible differences between the two SK enzymes in relation to the structural 
changes required for product release, MD simulation studies were also performed with Hp-SK 
(Figure 5). The dynamic behavior of Hp-SK/ADP/2 was studied by using the enzyme geometries 
found in the crystal structures of Hp-SK (PDB code 3MUF
19
) in complex with ADP and shikimate-3-
phosphate (2).
 
The monomer of Hp-SK immersed in a truncated octahedron of water molecules 
obtained using the molecular mechanics force field AMBER was used.
21
 The results from 50 ns of 
dynamic simulation showed significant differences between the two enzymes. In general, for the Hp-
SK enzyme the release of 2 from the active site is a much slower process since it is not initiated until 
around 7 ns of dynamic simulation and this process requires to be performed at 50 ºC. For the Mt-SK 
enzyme, a large motion of the SB domain was already observed after 20 ps of dynamic simulation 
at 25 ºC.
18
 Even bearing in mind that the computational time cannot be correlated with the velocity 
of an enzyme, this finding is consistant with the huge velocity differences observed experimentally 
between the two enzymes. Thus, under the same assay conditions, Hp-SK has a kcat value that is 
2500-fold lower than that for Mt-SK. More importantly, the motion of the SB domain is also 
different. Whereas for the Mt-SK enzyme a synchronous and large opening of the three -helices 2 
(7 Å), 3 (10 Å) and 5 (6 Å) was observed (Figure 5B), which is reminiscent of the movement 
of an accordion, for the Hp-SK enzyme an asynchronous and more reduced opening was observed 
(Figures S2-S4). Thus, conformational changes were mainly focused on -helices 5 (4 Å) and 3 
(3 Å), which in both cases were less pronounced than in the M. tuberculosis enzyme (Figure 5B). 
An opening of only a 2 Å was observed for the -helix 2. In contrast, significant differences were 
not observed in the opening of the LID domain, which was very large in both cases (up to 10 Å). 
Overall, the LID undergoes a large opening as for Mt-SK and part of the SB domain twists to create 
an additional gap in this region. These findings suggest that the ‘dynamic pocket’ in the SB domain 
of Hp-SK would be smaller and distinct from that in Mt-SK. In both cases the three conserved 
arginines are responsible for removing the product from the active site through strong electrostatic 
interactions between their guanidinium groups and the phosphate group in 2. In addition, for the Hp-
SK enzyme the presence of an arginine in -helix 3 (Arg45) instead of an alanine (Ala46) in Mt-
SK, which is oriented towards the active site, allows this residue to also be involved in product 
release (Figures 5C–5G).  
Analysis of the available crystal structures and the amino acid sequence of various SK enzymes 
reveals that the apolar pocket surrounding the C4 and C5 hydroxyl groups of the natural substrate 
(SB domain), which undergoes the aforementioned motion, is quite conserved (Figures S5 and 6). 
This pocket mainly involves the conserved residues Phe48/Phe49, Phe56/Phe57, Ile36/Ile37 and 
Val44/Ile45 (in H. pylori and M. tuberculosis, respectively). In addition, further sealing from the bulk 
water is achieved by several apolar residues in the vicinity (for Hp-SK: Leu51, Leu42, Val40 and 
Ile47; for Mt-SK: Ile60 and Ile48) and this also prevents the entry of water from the environment. 
Reasoning that the incorporation of benzyl groups in the C5 position of shikimic acid (1) would 
allow favorable contacts to be established with the apolar residues within the pocket and would 
prevent the appropriate closure of the active site for catalysis, we decided to explore the possible 
inhibition of the SK enzyme by compounds 3–6. A range of substituted benzene rings were 
incorporated. Docking studies suggested that meta-substituted derivatives would lead to a more 
favorable effect than the corresponding para-substituted ones as the group would be pointing 
towards the protein. In addition, considering that Mt-SK appears to be able to achieve a wider 
opening of the SB domain than Hp-SK, we also studied the effect of larger aromatic moieties 
(naphthalene, benzothiophene, indole), compounds 3h–3i and 4–5. Finally, the effect of replacing the 
C3 hydroxyl group in O-benzyl derivatives 3 by an amino group was also analyzed with compounds 
6. 
Synthesis of Compounds 3 – The synthesis of O-benzyl shikimic acid derivatives 3 was carried out 
from the previously described alcohol 8,
22
 which is synthesized in two steps from commercially 
available shikimic acid (1) (Scheme 2). Alkylation of alcohol 8 with various benzyl bromide 
derivatives in the presence of sodium iodide and diisopropylethylamine at 150 ºC afforded benzyl 
ethers 9. Removal of the acetal group in 9 with HCl followed by basic hydrolysis of the resulting 
esters 10 and, in some cases, subsequent protonation with Amberlite IR-120 (H
+
) ion-exchange resin 
gave the O-benzyl shikimic acid derivatives 3 or their corresponding sodium salts. For compounds 
9d and 9f, treatment with HCl directly afforded the corresponding acids 3d and 3f, respectively. 
Synthesis of Compounds 4 and 5 – The triazole moiety in 4–5 was introduced by a copper(I)-
catalyzed 1,3-dipolar cycloaddition between azide 14 and 3-phenyl-1-propyne or 3-phenoxy-1-
propyne, respectively (Scheme 3). Azide 14
23
 was prepared in four steps from protected methyl 
shikimate 11
24
 following a modified procedure. First, treatment of alcohol 11 with mesyl chloride in 
the presence of trimethylamine and subsequent acid hydrolysis of the acetal gave mesylate 12. 
Treatment of diol 12 with sodium methoxide and methanol afforded epoxide 13,
25
 which was treated 
with sodium azide to give the desired azide 14. The cycloaddition reaction regioselectively afforded 
the 4-substituted triazoles 15 and 16. Basic hydrolysis of the resulting methyl esters 15 and 16 and 
protonation with an ion-exchange resin, led to the desired acids 4 and 5. 
Synthesis of Compounds 6h–i – The C3 amino group in compounds 6h and 6i was introduced by 
Mitsunobu reaction between diols 10h–i and freshly prepared hydrazoic acid followed by reduction 
of the resulting azides (Scheme 4). Finally, basic hydrolysis of the amino methyl esters 17h–i gave 
the desired amines 6h–i. 
Inhibitory Activity and Susceptibility Testing – The inhibitory properties of compounds 3–6 
against both SK enzymes were tested. Enzyme activity was measured by UV monitoring of ADP 
formation by coupling the released ADP to the oxidation of NADH using pyruvate kinase (PK) and 
lactate dehydrogenase (LDH) as coupling enzymes. The disappearance of NADH by oxidation to 
NAD during PK-LDH activity was monitored at 340 nm. All of the compounds that were found not 
to be substrates for this enzyme were assayed in the presence of shikimic acid (1) and ATP for their 
inhibitory properties against Mt-SK and Hp-SK. All compounds proved to be reversible competitive 
inhibitors of both enzymes. The inhibition data (Ki), which were obtained from Dixon plots (1/v vs 
[I]), are provided in Table 1. 
In general, the reported compounds proved to be more potent against Hp-SK than Mt-SK. 
Compounds 4–6 were found to have Ki values above the Km (Table 1, entries 10–13). In contrast, 
compounds 3, which bear O-benzyl groups, were the best inhibitors for both enzymes with Ki values 
below Km in most cases (Table 1, entries 1–9). For Hp-SK, the latter compounds were found to have 
Ki values in the low micromolar or nanomolar range. The results show that the incorporation of 
substituents in the meta-position of the benzene ring and the use of large aromatic rings enhances the 
inhibitory potency by up to 36-fold. The most potent inhibitor in series 3 was the 3-nitrobenzyl 
derivative 3e, which gave Ki values of 0.46 µM and 10 µM against Hp-SK and Mt-SK, respectively 
(Table 1, entry 5). 5-Benzothiophenyl derivative 3i was also potent, with a Ki value of 0.56 µM 
against Hp-SK. In view of the high inhibitory potency of the 3-nitrobenzyl derivative 3e against both 
enzymes, the high Ki values obtained with the perfluoro derivative 3g are surprising (Table 1, entry 
7). Compounds 3i and 3e proved to inhibit more efficiently Hp-SK than previously reported ones.
19 
The in vitro anti-Helicobacter pylori activity of the most potent inhibitors of series 3, compounds 3e 
and 3i, and compounds 46 was studied. Considering the high hydrophilicity of these compounds 
due to the presence of a carboxylate group, which is required for enzyme recognition by the 
conserved Arg132, their corresponding methyl ester prodrugs (compounds 10e, 10i, 1516 and 17h-
i) were employed. We have previously used this strategy to achieve the internalization into 
mycobacterial cell of diverse reversible competitive inhibitors of the type II dehydroquinase, the 
third enzyme of the shikimic acid pathway.
26
 In the latter case, the free acids also proved to have low 
in vitro activity. The agar dilution method was used to determine the Minimum Inhibitory 
Concentration (MICs, µg/mL) of the compounds, according to the standard method recommended by 
CLSI.
27 
A H. pylori clinical isolate obtained from a biopsy of a patient of the Guadalajara Hospital 
(Guadalajara, Spain) was employed. MICs were defined as the lowest concentration of each 
compound that completely inhibited visible growth on plates. MIC assays were performed at least 
three times. The results are provided in Table 2. The methyl ester 10i, which is the ester prodrug of 
the 5-benzothiophenyl derivative 3i with a Ki value of 560 nM, proved to be the most potent with an 
MIC value of 4 µg/mL. Derivative 10e proved to have a 32-fold higher MIC value, which might be 
due to the lower stability of the nitrobenzyl moiety vs the benzothiophenyl one. As expected, higher 
MICs values were obtained for methyl esters 1516 and 17h-i. 
In an effort to obtain further details of the binding interactions responsible for the inhibitory activity, 
the binding modes of compounds 3–6 with Mt-SK and Hp-SK were studied. Molecular docking 
using GOLD 5.2
20
 was initially carried out with diverse inactive open forms of the SK active site. 
The proposed binding modes were further analyzed by MD simulation studies and the results are 
discussed below. 
Binding Mode – Diverse inactive open conformations of the two enzymes, which were obtained by 
MD simulation studies, were employed for docking studies. For the Hp-SK enzyme, the first 15 ns of 
the MD simulation of the Hp-SK products complex provided diverse poses of the LID and SB 
domains in the open conformation. However, for the Mt-SK enzyme, the MD simulation performed 
with the Mt-SK/ADP/2 complex showed that as soon as the simulation starts large displacements in 
the positions of the conserved and essential active site residues occur. For instance, this is the case 
for the conserved Arg136, which is the key residue for carboxylate recognition in the substrate. 
Considering that under these circumstances the binding mode determined by GOLD might be quite 
unrealistic, diverse poses from the MD simulation of Mt-SK/ATP/(6R)-6-hydroxyshikimic acid were 
employed for docking studies (Figures 3C and 3D). The latter compound seemed to cause the 
opening of the SB domain (4 Å) due to a conformational change to the most stable conformation of a 
cyclohexene ring but without large displacements of the conserved arginines.
18
 
In general, as one would expect from the incorporation of a large substituent in the C5 position of 1, 
all of the ligands bind in the active site with the most stable conformation for a cyclohexene ring, i.e., 
with the C4 and C5 substituents in a pseudo-diequatorial disposition. The rigidity that the triazole 
moiety imparts to compounds 4 and 5 would disfavor their binding because the benzyl moiety would 
be more restricted in terms of finding the optimal conformation to achieve good binding with the 
apolar pocket – a situation that might explain their low inhibitory potency. The same limitation was 
observed with the incorporation of an amino group in the C3 position (compounds 6h and 6i). This 
group would cause the ligands to be in close contact with the γ-phosphate of ATP due to attractive 
electrostatic interactions between the phosphate group and the protonated amino group of the 
ligands. Fortunately, O-benzyl derivatives 3 proved to bind in the active site of the two SK enzymes, 
with the aromatic moiety interacting with the apolar pocket of the SB domain as desired. The highest 
score solutions of the most potent inhibitors, specifically compound 3e for Mt-SK and compounds 
3e, 3b, and 3i for Hp-SK, were further evaluated by MD simulation studies in order to assess the 
stability and therefore the reliability of the proposed binding mode. The results of the MD simulation 
studies (50 ns) show that the aforementioned complexes are stable as relevant differences were not 
observed in the position of the ligand during most of the simulation. Overall, our computational 
studies revealed that there are significant differences in the conformational changes caused by the 
ligands in the LID and SB domains based on the size of the aromatic moiety incorporated on the C5 
hydroxyl group as well as the type of SK enzyme. The results of these studies are discussed below. 
O-Benzyl derivative 3e – The binding mode of the most potent inhibitor of the monobenzyl series for 
the two enzymes, namely the nitro derivative 3e, proved to be significantly different in the active 
sites of Mt-SK (Figures 7A and 7D) and Hp-SK (Figures 7B and 7E). In the case of Mt-SK, the 
incorporation of the 3-nitrobenzyl moiety at the C5 position of 1 would cause the opening of the LID 
domain (9 Å) and -helix 3 of the SB domain (5 Å). This aromatic moiety would cause a large 
conformational change in the position of the essential arginine and a reduction in the flexibility of the 
LID and SB domains through a set of favorable lipophilic interactions with apolar residues of these 
domains. The 3-nitrobenzyl moiety would be trapped between the essential residues Phe49 and 
Arg117 by establishing π-π stacking and cation-π interactions, respectively. The interaction with the 
essential arginine seems to be crucial to enhance the binding affinity of the ligands in the active site 
and therefore their inhibitory potency. The nitro group would be pointing towards -helix 3. In this 
arrangement the benzyl group would interact with the side chains of Ile45 and Phe57 (-helix 3) 
and with the side chain of Val116 and the carbon chain of Arg117 of the LID. In contrast, for the Hp-
SK enzyme the 3-nitrobenzyl moiety in 3e would stabilize an open conformation of the SB domain 
(mainly -helices 2 and 5) by interaction with the apolar pocket between -helices 3 and 5, 
instead of -helix 3 (Figures 7B and 7E). Significant changes were not observed in the position of 
the essential arginine and the LID domain. The 3-nitrobenzyl moiety would now be located between 
the essential Phe48 and the carbon side chain of the conserved residue Glu53, with the nitro group 
pointing towards the LID domain instead of towards -helix 3. In this arrangement the benzyl 
group would establish π-π stacking interactions with Phe48 and lipophilic interactions with the side 
chains of Ile47, Leu51 and Glu53 (carbon chain). Moreover, the C5 CH group in 3e would interact 
with the side chain of Phe56 and the aromatic ring and the C6 methylene group would contact the 
side chain of Leu118, which is located in the LID. 
O-Benzyl derivative 3b – The introduction of a large and apolar methoxy group in the benzyl ring, 
namely compound 3b, which had a Ki of 1 µM against Hp-SK, would also stabilize an open 
conformation of the LID domain (Figures 7C and 7H). By establishing favorable lipophilic 
interactions with Leu118, the ligand is more embedded in the active site and this allows apolar 
interactions between the side chain of Met10 and the C3 and C4 CH bonds of the cyclohexene ring. 
Moreover, this compound also locates its benzyl group in the apolar pocket between -helices 3 
and 5 but causes the opening of -helix 5 only. The main difference with compound 3e with 
respect to the lipophilic interactions with side chain residues Ile47, Phe56 and Phe48 is the lack of a 
π-π stacking interaction between the benzyl moiety in 3b and the essential Phe48, which might 
account for the lower inhibitory potency. 
In general, the results of our MD simulation studies revealed that the substituent in the meta-position 
in 3 would prefer to point towards the LID domain in the two SK enzymes. The exception to this 
trend is the 3-nitrobenzyl derivative 3e when it binds with Mt-SK. In this case, the essential Arg117 
seems to select the opposite arrangement to establish a strong cation-π interaction with the ring – an 
interaction that was not observed in the other analogs of the series or with the Hp-SK enzyme. In 
order to obtain further evidence for this trend, MD simulation studies with the 3-nitro derivative 3e 
and the 3-methoxybenzyl derivative 3b were carried out with the two possible orientations of the 
substituent, i.e., pointing toward the LID or the SB domains. The binding free energies of these 
ligands were calculated using the MM/PBSA
28
 approach in explicit water (generalized Born, GB) as 
implemented in Amber. For Mt-SK, the calculated binding energy of the 3-nitrobenzyl derivative 3e 
when the nitro group is pointing towards the SB domain is –23.1 kcal lower than for the opposite 
pose. In addition, the 3-methoxybenzyl derivative 3b arranged with the methoxy group pointing 
towards the SB domain undergoes a rotation of 180° during the 50 ns of simulation to give the 
opposite pose. For Hp-SK, the calculated binding energy of 3b with the methoxy group pointing 
towards the LID domain is –16.7 kcal lower than that for the opposite pose. A less marked difference 
between the two poses was obtained for the nitro compound 3e (1.9 kcal). However, the 
aforementioned binding mode provides a more stable complex during the whole simulation. 
O-Benzyl derivative 3i – The benzothiophene derivative 3i, which had a Ki value of 560 nM against 
Hp-SK, was predicted to have a similar binding mode to the 3-methoxy derivative 3b (Figures 7G 
and 7H). Thus, this compound would also stabilize an open conformation of the LID (5 Å) and the 
SB (3 Å) domains. As shown in Figure 7I, although both ligands interact with the same residues, the 
arrangement and rigidity of the benzothiophene ring would probably enhance the binding, which 
might account for the 2-fold higher inhibitory potency. 
CONCLUSIONS AND FINAL REMARKS 
Several C5-substituted shikimic acid analogs, compounds 3–6, have been synthesized and tested 
against SK from M. tuberculosis and H. pylori, an essential enzyme in bacteria. These compounds 
were designed to explore the possible inhibition of the SK enzyme by blocking the appropriate 
closed form for catalysis. The two enzymes were found to undergo large conformational changes for 
product release in the LID and SB domains but they were particularly distinct in the latter domain. 
Specifically, the ‘dynamic apolar pocket’ that isolates the substrate for catalysis and involves a quite 
conserved region of -helices 2, 3 and 5 is significantly smaller for the Hp-SK enzyme and this 
proved to have an intrinsically different motion for the two enzymes. 
Compounds 3–6 are reversible competitive inhibitors of both SK enzymes but, in general, they are 
more potent against the H. pylori, having Ki values in the low micromolar or nanomolar range. 
Compounds 3, which contain an O-benzyl moiety, were the best inhibitors for both enzymes. Among 
the O-benzyl series 3, the 3-nitrobenzyl derivative 3e was found to be the most potent against the two 
enzymes and this compound had Ki values of 460 nM and 10 µM against Hp-SK and Mt-SK, 
respectively. The results of our MD simulation studies revealed that the 3-nitrobenzyl derivative 3e 
would cause the opening of the LID domain (9 Å) and -helix 3 (5 Å) of the SB domain of Mt-SK 
and a large conformational change in the position of the essential arginine by establishing a cation-π 
interaction with the nitrobenzyl ring of the ligand, with the nitro group pointing towards the SB 
domain. In contrast, for the Hp-SK enzyme, compound 3e would mainly cause the opening of the 
region between -helices 3 and 5 instead of -helix 3, an interaction with the essential arginine 
would not be established and the nitro group would be oriented towards the LID domain. 
5-Benzothiophenyl derivative 3i proved to be a potent reversible competitive inhibitor of Hp-SK (Ki 
= 560 nM). This compound would stabilize an open conformation of the LID (5 Å) and SB (3 Å) 
domains through a set of favorable apolar interactions with this ‘dynamic apolar pocket’. Moreover, 
compound 10i, a prodrug of inhibitor 3i, was the most efficient derivative in achieving good in vitro 
activity against Helicobacter pylori, having a MIC value of 4 µg/mL. 
The results from the studies described here have identified a good scaffold for the design of 
reversible competitive inhibitors of the SK enzyme and have opened up new opportunities for the 
development of novel inhibitors by targeting the dynamic apolar pocket that surrounds the C4 and 
C5 hydroxyl groups of the natural substrate. Moreover, these studies also represent a good example 
of the importance in drug design of taking into account the motion of an enzyme target. Thus, 
stabilization of the inactive and inappropriate conformation for enzymatic catalysis seems to also be 
a good approach for the development of inhibitors that can be used as drugs.  
Experimental Section 
General. All starting materials and reagents were commercially available and were used without 
further purification unless is indicated. 
1
H NMR spectra (250, 300 and 500 MHz), 
13
C NMR spectra 
(63, 75 and 125 MHz), 
31
P NMR spectra (202 MHz) and 
19
F NMR spectra (282 MHz) were 
measured in deuterated solvents. J values are given in Hertz. NMR assignments were carried out by a 
combination of 1 D, COSY, and DEPT-135 experiments. FT-IR spectra were recorded as NaCl 
plates or KBr discs in a PerkinElmer Two FTIR spectrometer with attenuated total reference. [α]D
20 = 






. MilliQ deionized water was used in all the buffers. All 
procedures involving the use of ion-exchange resins were carried out at room temperature using 
Milli-Q deionized water. Amberlite IR-120 (H
+
) (cation exchanger) was washed alternately with 
water, 10% NaOH, water, 10% HCl, and finally water before use. The spectroscopic measurements 
were made on a Varian Cary 100 UV-Vis spectrophotometer with a 1 cm pathlength cell fitted with a 
Peltier temperature controller. The purity of compounds 36 was analyzed by HPLC and by NMR. 
For compounds 35, HPLC was performed on a Bio-Rad Aminex ion exclusion HPX-87H organic 
acids column (300 mm × 16 mm), eluting with 100 mM aqueous formic acid at a flow rate of 0.6 mL 
min
1
. For compounds 6, a Phenomenex Luna 5 µM C18 column (250 mm × 4.6 mm), eluting with a 
gradient of acetonitrile/water [from (5:95) to (30:70)] at a flow rate of 1 mL min
–1
, was employed. 
All tested compounds have a purity ≥95%. 
General procedure for the synthesis of compounds 9  A solution of alcohol 8
22
 (1 equivalent), 
N,N-diisopropylethylamine (1.6 equivalents), benzyl bromide (1.5 equivalents) and sodium iodide 
(0.1 equivalents) under inert atmosphere, was heated at 150 °C for 1.54.5 h. After cooling to room 
temperature, the resulting brown residue was dissolved in a mixture of ethyl acetate and saturated 
solution of sodium bisulfate. The organic layer was separated and the aqueous layer was extracted 
with ethyl acetate (3). The combined organic extracts were dried (Na2SO4 anh.), filtered and 
concentrated under reduced pressure. The resulted reside was purified by flash chromatography to 
give benzyl ethers 9. 
Methyl (3R,4S,5R)-5-benzyloxy-3,4-(O-isopropiliden)cyclohex-1-ene-1-carboxylate (9a)  
Alcohol 8 (100 mg, 0.44 mmol), N,N-diisopropylethylamine (0.12 mL, 0.70 mmol), benzyl bromide 
(78 L, 0.66 mmol) and sodium iodide (6.6 mg, 0.044 mmol). Reaction time = 4.5 h. 
Chromatographic eluent: (20:80) diethyl ether/hexane. 9a (47 mg, 39%) as a yellow oil. 
20][ D = –
39.0º (c2.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.30 (m, 5H, 5×ArH), 6.88 (m, 1H, H2), 4.75 
(m, 1H, H3), 4.70 (d, J = 12.0 Hz, 1H, OCHH), 4.64 (d, J = 12.0 Hz, 1H, OCHH), 4.26 (t, J = 6.3 
Hz, 1H, H4), 3.77 (m, 1H, H5), 3.76 (s, 3H, OCH3), 2.70 (dd, J = 4.2 and 17.4 Hz, 1H, H6eq), 2.40 
(dd, J = 6.6 and 17.4 Hz, 1H, H6ax) and 1.39 (br s, 6H, 2CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 
166.7 (C), 138.1 (C), 134.6 (CH), 129.5 (C), 128.3 (2CH), 127.6 (3CH), 109.4 (C), 75.9 (CH), 
74.6 (CH), 72.3 (CH), 71.5 (OCH2), 52.0 (OCH3), 27.8 (CH3), 26.1 (CH2) and 25.8 (CH3) ppm. IR 
(film) ʋ: 1722 (CO) cm
-1
. MS (ESI) m/z = 341 (MNa
+
). HRMS calcd for C18H22O5Na (MNa
+
): 
341.1359, found 341.1352. 
Methyl (3R,4S,5R)-5-(3-methoxybenzyloxy)-3,4-(O-isopropiliden)cyclohex-1-ene-1-carboxylate 
(9b)  Alcohol 8 (100 mg, 0.44 mmol), N,N-diisopropylethylamine (0.12 mL, 0.70 mmol), 3-
metoxybenzyl bromide (92 L, 0.66 mmol) and sodium iodide (6.6 mg, 0.044 mmol). Reaction time 
= 1.5 h. Chromatographic eluent: (25:75) diethyl ether/hexane. 9b (47 mg, 31%) as a yellow oil. 
20][ D = –93.2º (c0.2, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.23 (t, J = 7.8 Hz, 1H, ArH), 6.92–
6.80 (m, 4H, 3ArHH2), 4.74 (m, 1H, H3), 4.66 (d, J = 12.6 Hz, 1H, OCHH), 4.62 (d, J = 12.6 Hz, 
1H, OCHH), 4.25 (t, J = 6.3 Hz, 1H, H4), 3.79 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 2.69 (dd, J = 3.6 
and 17.4 Hz, 1H, H6eq), 2.39 (dd, J = 6.6 and 17.4 Hz, 1H, H6ax) and 1.38 (br s, 6H, 2CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.7 (C), 159.7 (C), 139.8 (C), 134.6 (CH), 129.5 (C), 129.3 (CH), 
119.9 (CH), 113.2 (CH), 113.0 (CH), 109.4 (C), 75.9 (CH), 74.6 (CH), 72.3 (CH), 71.4 (OCH2), 55.1 
(OCH3), 52.0 (OCH3), 27.8 (CH3), 26.1 (CH2) and 25.8 (CH3) ppm. IR (film) ʋ: 1710 (CO) cm
-1
. MS 
(ESI) m/z = 371 (MNa
+
). HRMS calcd for C19H24O6Na (MNa
+
): 371.1465, found 371.1469. 
Methyl (3R,4S,5R)-5-(3-fluorobenzyloxy)-3,4-(O-isopropiliden)cyclohex-1-ene-1-carboxylate 
(9c)  Alcohol 8 (100 mg, 0.44 mmol), N,N-diisopropylethylamine (0.12 mL, 0.70 mmol), 3-
fluorobenzyl bromide (81 L, 0.66 mmol) and sodium iodide (6.6 mg, 0.044 mmol). Reaction time = 
2 h. Chromatographic eluent: (30:70) diethyl ether/hexane. 9c (61 mg, 47%) as a yellow oil. 
 20][ D = –63.4º (c0.8, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.27 (m, 1H, ArH), 7.08 (m, 2H, 
2ArH), 6.97–6.89 (m, 2H, ArH+H2), 4.75 (m, 1H, H3), 4.68 (d, J = 13.2 Hz, 1H, OCHH), 4.64 (d, 
J = 13.2 Hz, 1H, OCHH), 4.25 (t, J = 6.6 Hz, 1H, H4), 3.76 (s, 3H, OCH3), 3.67 (m, 1H, H5), 2.72 
(dd, J = 3.6 and 17.4 Hz, 1H, H6eq), 2.36 (dd, J = 6.9 and 17.4 Hz, 1H, H6ax) and 1.39 (s, 6H, 
2CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.6 (C), 162.9 (C, JC-F = 244 Hz), 140.9 (C, JC-F = 7 
Hz), 134.5 (CH), 129.8 (CH, JC-F = 8 Hz), 129.6 (C), 122.8 (CH, JC-F = 3 Hz), 114.5 (CH, JC-F = 32 
Hz), 114.2 (CH, JC-F = 34 Hz), 109.5 (C), 76.1 (CH), 75.0 (CH), 72.3 (CH), 70.7 (OCH2), 52.0 
(OCH3), 27.7 (CH3), 26.2 (CH2) and 25.7 (CH3) ppm. IR (film) ʋ: 1710 (CO) cm
-1
. MS (ESI) m/z = 
359 (MNa
+
). HRMS calcd for C18H21O5FNa (MNa
+
): 359.1265, found 359.1269. 
Methyl (3R,4S,5R)-5-(3-methylbenzyloxy)-3,4-(O-isopropiliden)cyclohex-1-ene-1-carboxylate 
(9d)  Alcohol 8 (284.5 mg, 2.25 mmol), N,N-diisopropylethylamine (0.35 mL, 2.0 mmol), 3-
methylbenzyl bromide (0.25 mL, 1.88 mmol) and sodium iodide (19 mg, 0.125 mmol). Reaction 
time = 1.5 h. Chromatographic eluent: (40:60) diethyl ether/hexane. 9d (166.3 mg, 40%) as a yellow 
oil. 
20][ D = 55.7 º (c1.0, CHCl3). 
1
H NMR (250 MHz, CDCl3) δ: 7.21 (d, J = 7.3 Hz, 1H, ArH), 7.16 
(s, 2H, 2×ArH), 7.10 (t, J = 5.5 Hz, 1H, ArH), 6.89 (m, 1H, H2), 4.76 (m, 1H, H3), 4.67 (d, J = 12.0 
Hz, 1H, OCHH), 4.61 (d, J = 12.0 Hz, 1H, OCHH), 4.26 (t, J = 6.3 Hz, 1H, H4), 3.79 (m, 1H, H5), 
3.77 (s, 3H, OCH3), 2.762.67 (m, 1H, H6ax), 2.402.35 (m, 1H, H6eq), 2.35 (s, 3H, CH3) and 1.40 
(s, 6H, 2×CH3) ppm. 
13
C NMR (63 MHz, CDCl3) δ: 166.8 (C), 138.0 (2×C), 134.7 (CH), 129.6 (C), 
128.5 (2×CH), 128.3 (CH), 124.9 (CH), 109.4 (C), 75.9 (CH), 74.5 (CH), 72.3 (OCH3), 71.5 
(OCH2), 52.1 (CH), 27.9 (CH3), 26.1 (CH2), 25.9 (CH3) and 21.4 (CH3) ppm. IR (ATR) ʋ: 1714 
(CO) cm
1
. MS (ESI) m/z = 355 (MNa
+
). HRMS calcd for C19H24NaO5 (MNa
+
): 355.1516; found, 
355.1516. 
Methyl (3R,4S,5R)-5-(3-nitrobenzyloxy)-3,4-(O-isopropyliden)cyclohex-1-eno-1-carboxylate 
(9e)  Alcohol 8 (115 mg, 0.50 mmol), N,N-diisopropylethylamine (0.14 mL, 0.80 mmol), 3-
nitrobenzyl bromide (162 mg, 0.75 mmol) and sodium iodide (7.5 mg, 0.05 mmol). Reaction time = 
1.5 h. Chromatographic eluent: (30:70) ethyl acetate/hexane. 9e (58.1 mg, 32%) as a yellow oil.  
20][ D = –51.8º (c1.3, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 8.22 (br s, 1H, ArH), 8.13 (d, J = 8.4 
Hz, 1H, ArH), 7.68 (d, J = 7.6 Hz, 1H, ArH), 7.50 (t, J = 8.0 Hz, 1H, ArH), 6.91 (br s, 1H, H2), 4.77 
(s, 2H, OCH2), 4.70 (br s, 1H, H3), 4.22 (t, J = 6.6 Hz, 1H, H4), 3.77 (s, 3H, OCH3), 3.72 (m, 1H, 
H5), 2.78 (dd, J = 3.5 and 17.5 Hz, 1H, H6ax), 2.40−2.32 (m, 1H, H6eq) and 1.40 (s, 6H, 2×CH3) 
ppm. 
13
C NMR (63 MHz, CDCl3) δ: 166.6 (C), 148.4 (C), 140.7 (C), 134.7 (CH), 133.4 (CH), 129.8 
(C), 129.4 (CH), 122.7 (CH), 122.4 (CH), 109.7 (C), 76.5 (CH), 76.1 (CH), 72.5 (CH), 70.5 (OCH2), 
52.3 (OCH3), 27.9 (CH3), 26.6 (CH2) and 25.8 (CH3) ppm. IR (ATR) ʋ: 1710 (CO) and 1531 (NO) 
cm
–1
. MS (ESI) m/z = 386 (MNa
+
). HRMS calcd for C18H21NO7Na (MNa
+
): 386.1210; found, 
386.1216. 
Methyl (3R,4S,5R)-5-(4-methylbenzyloxy)-3,4-(O-isopropiliden)cyclohex-1-ene-1-carboxylate 
(9f)  Alcohol 8 (250 mg, 1.10 mmol), N,N-diisopropylethylamine (0.30 mL, 1.76 mmol), 4-
methylbenzyl bromide (305 mg, 1.65 mmol) and sodium iodide (16 mg, 0.11 mmol). Reaction time 
= 1.5 h. Chromatographic eluent: (40:60) diethyl ether/hexane. 9f (307 mg, 84%) as a yellow oil.  
20][ D = 50.2º (c1.1, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.23 (d, J = 8.0 Hz, 2H, 2×ArH), 7.13 
(d, J = 8.2 Hz, 2H, 2×ArH), 6.87 (m, 1H, H2), 4.73 (m, 1H, H3), 4.65 (d, J = 12.0 Hz, 1H, OCHH), 
4.59 (d, J = 12.0 Hz, 1H, OCHH), 4.24 (t, J = 6.2 Hz, 1H, H4), 3.77 (m, 1H, H5), 3.75 (s, 3H, 
OCH3), 2.712.64 (m, 1H, H6ax), 2.452.36 (m, 1H, H6eq), 2.33 (s, 3H, CH3) and 1.38 (s, 6H, 
2×CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.7 (C), 137.3 (C), 135.1 (C), 134.7 (CH), 129.5 (C), 
129.0 (2×CH), 127.8 (2×CH), 109.3 (C), 75.8 (CH), 74.3 (CH), 72.3 (CH), 71.3 (OCH2), 51.9 
(OCH3), 27.8 (CH3), 26.1 (CH2), 25.9 (CH3) and 21.1 (CH3) ppm. IR (ATR) ʋ: 1720 (CO) cm
1
. MS 
(ESI) m/z = 355 (MNa
+
). HRMS calcd for C19H24NaO5 (MNa
+
): 355.1516; found, 355.1517.  
Methyl (3R,4S,5R)-3,4-(O-isopropiliden)-5-(perfluorobenzyl)cyclohex-1-ene-1-carboxylate (9g) 
 Alcohol 8 (200 mg, 0.88 mmol), N,N-diisopropylethylamine (0.24 mL, 1.41 mmol), 
perfluorobenzyl bromide (0.2 mL, 1.32 mmol) and sodium iodide (13.2 mg, 0.09 mmol). Reaction 
time = 1.5 h. Chromatographic eluent: (10:90) diethyl ether/hexane. 9g (40 mg, 11%) as a yellow oil. 
 20][ D = 27.0° (c0.6, CHCl3). 
1
H NMR (500 MHz, CDCl3) δ: 6.89 (m, 1H, H2), 4.75 (dt, J = 2.0 
and 8.5 Hz, 1H, OCH2), 4.72 (m, 1H, H3), 4.19 (t, J = 6.5 Hz, 1H, H4), 3.77 (s, 3H, OCH3), 3.73 (dt, 
J = 4.5 and 7.0 Hz, 1H, H5), 2.73 (ddt, J = 17.5, 4.5 and 1.5 Hz, 1H, H6eq), 2.34 (ddt, J = 17.5, 2.9 
and 7.5 Hz, 1H, H6ax), 1.40 (s, 3H, CH3) and 1.39 (s, 3H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3) δ: 
166.5 (C), 146.6136.4 (m, 5C), 134.5 (CH), 129.5 (C), 111.4 (td, JC-F = 2 and 11 Hz, C), 109.6 
(C), 76.4 (CH), 76.1 (CH), 72.3 (CH), 58.8 (OCH2), 52.1 (OCH3), 27.7 (CH3), 26.4 (CH2) and 25.7 
(CH3) ppm. 
19
F NMR (282 MHz, CDCl3) δ: 142.9 (dd, J = 5 and 20 Hz, 2F), 153.9 (t, J = 20 Hz, 
1F) and 162.1 (dt, J = 7 and 20 Hz, 2F) ppm. IR (film) ʋ: 1722 (CO) cm
-1
. MS (ESI) m/z = 431 
(MNa
+
). HRMS calcd for C18H17F5O5Na (MNa
+
): 431.0888; found, 431.0889.  
Methyl (3R,4S,5R)-5-(2-naphthyl)methoxy-3,4-(O-isopropiliden)cyclohex-1-ene-1-carboxylate 
(9h)  Alcohol 8 (100 mg, 0.44 mmol), N,N-diisopropylethylamine (0.12 mL, 0.70 mmol), 2-
(bromomethyl)naphatalene (150 mg, 0.66 mmol) and sodium iodide (6.6 mg, 0.044 mmol). Reaction 
time = 3 h. Chromatographic eluent: gradient of diethyl ether/hexanes [(15:85) to (20:80)]. 9h (85 
mg, 59%) as a yellow oil.  20][ D = –52.1º (c0.9, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.81 (m, 
4H, 4×ArH), 7.48 (m, 3H, 3×ArH), 6.91 (m, 1H, H2), 4.87 (d, J = 12.6 Hz, 1H, OCHH), 4.82 (d, J = 
12.6 Hz, 1H, OCHH), 4.78 (m, 1H, H3), 4.31 (t, J = 6.3 Hz, 1H, H4), 3.84 (m, 1H, H5), 3.76 (s, 3H, 
OCH3), 2.75 (dd, J = 4.2 and 17.4 Hz, 1H, H6eq), 2.45 (dd, J = 6.6 and 17.4 Hz, 1H, H6ax) and 1.41 
(br s, 6H, 2CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.7 (C), 135.6 (C), 134.6 (CH), 133.2 (C), 
133.0 (C), 129.5 (C), 128.1 (CH), 127.8 (CH), 127.6 (CH), 126.4 (CH), 126.0 (CH), 125.8 (CH), 
125.6 (CH), 109.4 (C), 75.9 (CH), 74.6 (CH), 72.3 (CH), 71.6 (OCH2), 52.0 (OCH3), 27.8 (CH3), 
26.2 (CH2) and 25.8 (CH3) ppm. IR (film) ʋ: 1710 (CO) cm
-1
. MS (ESI) m/z = 391 (MNa
+
). HRMS 
calcd for C22H24O5Na (MNa
+
): 391.1516; found, 391.1523. 
Methyl (3R,4S,5R)-5-(benzo[b]thiophen-5-ylmethoxy)-3,4-(O-isopropiliden)cyclohex-1-ene-1-
carboxylate (9i)  Alcohol 8 (250 mg, 1.1 mmol), N,N-diisopropylethylamine (0.3 mL, 1.8 mmol), 
5-(bromomethyl)benzo[b]thiophene (373 mg, 1.6 mmol) and sodium iodide (16.5 mg, 0.11 mmol). 
Reaction time = 1.5 h. Chromatographic eluent: (40:60) diethyl ether/hexane. 9i (137 mg, 33%) as a 
yellow oil.  20][ D = 42.2° (c1.6, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.84 (d, J = 8.4 Hz, 1H, 
ArH), 7.80 (s, 1H, ArH), 7.43 (d, J = 5.4 Hz, 1H, ArH), 7.32 (m, 2H, 2ArH), 6.89 (m, 1H, H2), 
4.81 (d, J = 12.0 Hz, 1H, OCHH), 4.76 (m, 2H, OCHHH3), 4.28 (t, J = 6.3 Hz, 1H, H4), 3.81 (m, 
1H, H5), 3.75 (s, 3H, OCH3), 2.73 (dd, J = 4.5 and 17.4 Hz, 1H, H6eq), 2.42 (dd, J = 6.6 and 17.4 Hz, 
1H, H6ax), 1.40 (s, 3H, CH3) and 1.39 (s, 3H, CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.6 (C), 
139.6 (C), 139.0 (C), 134.5 (CH), 134.2 (C), 129.5 (C), 124.1 (CH), 123.7 (CH), 122.7 (CH), 122.5 
(CH), 122.3 (CH), 109.3 (C), 75.9 (CH), 74.4 (CH), 72.2 (CH), 71.5 (CH2), 51.9 (OCH3), 27.7 
(CH3), 26.1 (CH2) and 25.8 (CH3) ppm. IR (ATR) ʋ: 1710 (CO) cm
-1
. MS (ESI) m/z = 397 (MNa
+
). 
HRMS calcd for C20H22O5SNa(MNa
+
): 397.1080; found, 397.1091. 
General procedure for the synthesis of compounds 10  A solution of acetal 9 (1 equivalent) in 
ethanol (0.15 M) and aqueous solution of HCl (0.16 mL/mmol, 6 M) was heated at 60 °C for 1.54 
h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure 
and the resulting residue was purified by flash chromatography to give diol 10. 
Methyl (3R,4S,5R)-5-benzyloxy-3,4-dihydroxycyclohex-1-ene-1-carboxylate (10a)  Acetal 9a 
(45.8 mg, 0.15 mmol), ethanol (1 mL) and HCl (25 L, 6 M). Reaction time = 4 h. Chromatographic 
eluent: (75:25) diethyl ether/hexane. 10a (40 mg, 95%) as a yellow oil.  20][ D = –133.9º (c3.2, 
CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.34 (m, 5H, 5ArH), 6.86 (m, 1H, H2), 4.71 (d, J = 11.4 
Hz, 1H, OCHH), 4.51 (d, J = 11.4 Hz, 1H, OCHH), 4.48 (t, J = 4.2 Hz, 1H, H3), 3.88–3.78 (m, 2H, 
H4H5), 3.76 (s, 3H, OCH3), 2.93 (dd, J = 4.2 and 17.7 Hz, 1H, H6ax) and 2.27 (br dd, J = 6.9 and 
17.7 Hz, 1H, H6ax) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.8 (C), 137.8 (C), 136.0 (CH), 130.2 (C), 
128.5 (CH), 127.9 (CH), 127.6 (CH ), 74.1 (CH), 71.4 (OCH2), 70.9 (CH), 65.8 (CH), 52.0 (OCH3) 
and 28.5 (CH2) ppm. IR (film) ʋ: 3423 (OH) and 1715 (CO) cm
-1
. MS (ESI) m/z = 301 (MNa
+
). 
HRMS calcd for C15H18O5Na (MNa
+
): 301.1046; found, 301.1039. 
Methyl (3R,4S,5R)-3,4-dihydroxy-5-(3-methoxybenzyloxy)cyclohex-1-ene-1-carboxylate (10b)  
Acetal 9b (37 mg, 0.11 mmol), ethanol (0.7 mL) and HCl (18 L, 6 M). Reaction time = 1.5 h. 
Chromatographic eluent: (80:20) ethyl acetate/hexane. 10b (30 mg, 90%) as a colourless oil. 
 20][ D = –114.8º (c2.9, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.26 (t, J = 7.8 Hz, 1H, ArH), 6.87 
(m, 4H, 3×ArHH2), 4.69 (d, J = 11.7 Hz, 1H, OCHH), 4.48 (m, 2H, OCHHH3), 3.82 (m, 2H, 
H4H5), 3.80 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 2.93 (dd, J = 3.9 and 18.3 Hz, 1H, H6eq) and 2.26 
(dd, J = 6.3 and 18.3 Hz, 1H, H6ax) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.7 (C), 159.7 (C), 139.4 
(C), 135.9 (CH), 130.3 (C), 129.6 (CH), 120.0 (CH), 113.3 (CH), 74.1 (CH ), 71.3 (OCH2), 71.0 
(CH), 65.8 (CH), 55.2 (OCH3), 52.1 (OCH3) and 28.6 (CH2) ppm. IR (film) ʋ: 3432 (OH) and 1715 
(CO) cm
-1
. MS (ESI) m/z = 331 (MNa
+
). HRMS calcd for C16H20O6Na (MNa
+
): 331.1152; found, 
331.1156. 
Methyl (3R,4S,5R)-5-(3-fluorobenzyloxy)-3,4-dihydroxycyclohex-1-ene-1-carboxylate (10c)  
Acetal 9c (47 mg, 0.14 mmol), ethanol (0.9 mL) and HCl (25 L, 6 M). Reaction time = 4 h. 
Chromatographic eluent: (70:30) ethyl acetate/hexane. 10c (41 mg, 99%) as a yellow oil. 
20][ D = –
113.0º (c4.2, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.30 (m, 1H, ArH), 7.09–6.95 (m, 3H, ArH), 
6.90 (m, 1H, H2), 4.69 (d, J = 12.0 Hz, 1H, CHH), 4.52 (d, J = 12.0 Hz, 1H, CHH), 4.49 (t, J = 3.9 
Hz, 1H, H3), 3.83 (m, 2H, H4H5), 3.75 (s, 3H, OCH3), 2.90 (m, 1H, H6ax) and 2.27 (m, 1H, H6eq) 
ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.7 (C), 162.9 (C, JC-F = 245 Hz), 140.5 (C, JC-F = 7 Hz), 
136.1 (CH), 130.0 (CH, JC-F = 9 Hz), 123.0 (CH, JC-F = 3 Hz), 114.7 (CH, JC-F = 22 Hz), 114.4 (CH, 
JC-F = 22 Hz), 74.4 (CH), 70.9 (CH), 70.6 (OCH2), 65.9 (CH), 52.1 (OCH3) and 28.4 (CH2) ppm. IR 
(film) ʋ: 3431 (OH) and 1716 (CO) cm
-1
. MS (ESI) m/z = 319 (MNa
+
). HRMS calcd for 
C15H17O5FNa (MNa
+
): 319.0952; found, 319.0949. 
Methyl (3R,4S,5R)-3,4-dihydroxy-5-(3-nitrobenciloxy)cyclohex-1-ene-carboxylate (10e)  
Acetal 9e (56.2 mg, 0.15 mmol), ethanol (1 mL) and HCl (30 L, 6 M). Reaction time = 3 h. 
Chromatographic eluent: (60:40) ethyl acetate/hexane. 10e (27.2 mg, 56%) as a yellow oil. 
20][ D = –
171.5º (c1.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 8.20 (br s, 1H, ArH), 8.13 (d, J = 8.1 Hz, 1H, 
ArH), 7.65 (d, J = 7.5 Hz, 1H, ArH), 7.51 (t, J = 7.9 Hz, 1H, ArH), 6.86 (br s, 1H, H2), 4.79 (d, J = 
12.2 Hz, 1H, OCHH), 4.65 (d, J = 12.2 Hz, 1H, OCHH), 4.51 (br s, 1H, H3), 3.88 (m, 2H, H5+H4), 
2.95 (s, 1H, OH), 2.85 (m, 2H, OH+H6ax) and 2.29 (m, 1H, H6eq) ppm. 
13
C NMR (75 MHz, CDCl3) 
δ: 166.8 (C), 148.4 (C), 140.3 (C), 136.3 (CH), 133.4 (CH), 130.1 (C), 129.6 (CH), 122.9 (CH), 
122.3 (CH), 75.1 (CH), 71.0 (CH), 70.3 (CH), 66.1 (OCH2), 52.3 (OCH3) and 28.5 (CH2) ppm. IR 
(ATR): 3415 (OH), 1710 (CO) and 1525 (NO) cm
-1
. MS (ESI) m/z = 346 (MNa
+
). HRMS calcd for 
C15H17NO7Na (MNa
+
): 346.0897; found, 346.0907. 
Methyl (3R,4R,5R)-3,4-dihydroxy-5-((perfluorophenyl)methoxy)cyclohex-1-ene-1-carboxylate 
(10g)  Acetal 9g (73.5 mg, 0.18 mmol), ethanol (1.2 mL) and HCl (32 L, 6 M). Reaction time = 2 
h. Chromatographic eluent: (25:75) diethyl ether/hexane. 10g (43.7 mg, 66%) as a colourless oil. 
 20][ D = 92.6° (c1.3, CHCl3). 
1
H NMR (500 MHz, CDCl3) δ: 6.86 (m, 1H, H2), 4.79 (d, J = 11.0 
Hz, 1H, OCHH), 4.65 (d, J = 11.0 Hz, 1H, OCHH), 4.46 (t, J = 4.0 Hz, 1H, H3), 3.84 (dt, J = 5.0 and 
8.0 Hz, 1H, H5), 3.773.74 (m, 4H, OCH3H4), 2.97 (dd, J = 5.0 and 18.0 Hz, 1H, H6ax) 2.75 (br s, 
2H, 2OH) and 2.282.23 (m, 1H, H6eq) ppm. 
13
C NMR (125 MHz, CDCl3) δ: 166.6 (C), 
146.6136.5 (m, 5C), 135.8 (CH), 130.0 (C), 111.0 (td, JC-F = 3 and 18 Hz, C), 75.1 (CH), 70.9 
(CH ), 65.8 (CH ), 58.4 (OCH2), 52.1 (OCH3) and 28.5 (CH2) ppm. 
19
F NMR (282 MHz, CDCl3) δ: 
143.1 (dd, J = 7 and 21 Hz, 2F), 153.2 (t, J = 21 Hz, 1F) and 161.5 (dt, J = 8 and 21 Hz, 2F) 
ppm. IR (film): 3332 (OH) and 1716 (CO) cm
-1
. MS (ESI) m/z = 391 (MNa
+
). HRMS calcd for 
C15H13F5O5Na (MNa
+
): 391.0575; found, 391.0575. 
Methyl (3R,4S,5R)-3,4-dihydroxy-5-(2-naphthyl)methoxycyclohex-1-ene-1-carboxylate (10h)  
Acetal 9h (65 mg, 0.18 mmol), ethanol (1.2 mL) and HCl (30 L, 6 M). Reaction time = 3 h. 
Chromatographic eluent: (60:40) ethyl acetate/hexane. 10h (56 mg, 95%) as a colourless oil. 
 20][ D = –93.5º (c5.2, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.80 (m, 4H, 4×ArH), 7.47 (m, 3H, 
3×ArH), 6.86 (t, J = 1.5 Hz, 1H, H2), 4.84 (d, J = 11.7 Hz, 1H, OCHH), 4.65 (d, J = 11.7 Hz, 1H, 
OCHH), 4.48 (m, 1H, H3), 3.85 (m, 2H, H4H5), 3.75 (s, 3H, OCH3), 3.00–2.90 (m, 3H, 
2OH+CHH), and 2.31 (dd, J = 6.3 and 17.7 Hz, 1H, CHH) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 
166.8 (C), 136.1 (CH), 135.2 (C), 133.2 (C), 133.0 (C), 130.1 (C), 128.3 (CH), 127.8 (CH), 127.6 
(CH), 126.5 (CH), 126.3 (CH), 126.2 (CH), 126.0 (CH), 125.6 (CH), 74.1 (CH), 71.5 (OCH2), 70.9 
(CH ), 65.9 (CH ), 52.0 (OCH3) and 28.5 (CH2) ppm. IR (film) ʋ: 3427 (OH) and 1710 (CO) cm
-1
. 
MS (ESI) m/z = 351 (MNa
+
). HRMS calcd for C19H20O5Na (MNa
+
): 351.1203; found, 351.1196. 
Methyl (3R,4S,5R)-5-(benzo[b]thiophen-5-ylmethoxy)-3,4-dihydroxy-cyclohex-1-ene-1-
carboxylate (10f)  Acetal 9f (119.7 mg, 0.32 mmol), ethanol (2.1 mL) and HCl (57 L, 6 M). 
Reaction time = 4 h. Chromatographic eluent: (75:25) diethyl ether/hexane. 10h (30.4 mg, 90%) as a 
colourless oil. 
20][ D = 23.2° (c1.3, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.84 (d, J = 8.1 Hz, 1H, 
ArH), 7.76 (s, 1H, ArH), 7.44 (d, J = 5.4 Hz, 1H, ArH), 7.30 (m, 2H, 2ArH), 6.84 (m, 1H, H2), 
4.78 (d, J = 11.4 Hz, 1H, OCHH), 4.55 (d, J = 11.4 Hz, 1H, OCHH), 4.47 (m, 1H, H3), 3.893.76 
(m, 2H, H4H5), 3.74 (s, 3H, OCH3), 3.10 (br s, 2H, 2OH), 2.91 (dd, J = 4.2 and 17.7 Hz, 1H, 
H6eq) and 2.30 (dd, J = 6.6 and 17.7 Hz, 1H, H6ax) ppm. 
13
C NMR (75 MHz, CDCl3) δ: 166.8 (C), 
139.6 (C), 139.2 (C), 136.2(CH), 133.9 (C), 130.0 (C), 127.0 (CH), 124.2 (CH), 123.7 (CH), 122.8 
(CH), 122.5 (CH), 74.0 (CH), 71.4 (CH2), 70.8 (CH), 65.9 (CH), 52.0 (OCH3) and 28.4 (CH2) ppm. 
IR (ATR) ʋ: 3406 (OH) and 1707 (CO) cm
-1
. MS (ESI): 357 (MNa
+
). HRMS calcd for C17H18O5SNa 
(MNa
+
): 357.0767; found, 357.0772. 
(3R,4R,5R)-3,4-dihydroxy-5-(3-methylbenzyloxy)cyclohex-1-ene-1-carboxylic acid (3d)  A 
solution of compound 9d (166.3 mg, 0.50 mmol) in ethanol (3.4 mL) and aqueous solution of HCl 
(3.2 mL, 6 M) was heated at 60 °C for 3 h. After cooling to room temperature, the reaction mixture 
was concentrated under reduced pressure and the resulting residue was purified by flash 
chromatography, eluting with (60:40) ethyl acetate/hexane, to give acid 3d (42.3 mg, 30%), as a 
yellow oil. 
20][ D = 90.6º (c1.0, CH3OH). 
1
H NMR (300 MHz, CD3OD) δ: 7.177.07 (m, 3H, 
3×ArH), 7.02 (t, J = 7.0 Hz, 1H, ArH), 6.73 (br s, 1H, H2), 4.55 (d, J = 11.9 Hz, 1H, OCHH), 4.50 
(d, J = 11.9 Hz, 1H, OCHH), 4.35 (br s, 1H, H3), 3.79 (m, 2H, H4H5), 2.58 (br d, J = 18.3 Hz, 1H, 
H6ax), 2.29 (m, 1H, H6eq) and 2.26 (s, 3H, CH3) ppm. 
13
C NMR (75 MHz, CD3OD) δ: 170.0 (C), 
139.8 (C), 139.3 (CH), 139.0 (C), 130.3 (C), 129.4 (CH), 129.3 (CH), 129.2 (CH), 125.9 (CH), 76.4 
(CH), 72.5 (OCH2), 70.8 (CH), 67.4 (CH), 28.4 (CH3) and 21.4 (CH2) ppm. IR (ATR): 3409 (OH) 
and 1695 (CO) cm
1
. MS (ESI) m/z = 277 (MH). HRMS calcd for C15H17O5 (MH): 277.1081; 
found, 277.1081. 
(3R,4R,5R)-3,4-dihydroxy-5-(4-methylbenzyloxy)cyclohex-1-ene-1-carboxylic acid (3f)  A 
solution of compound 9f (306.7 mg, 0.92 mmol) in ethanol (6.1 mL) and aqueous solution of HCl (6 
mL, 6 M) was heated at 60 °C for 3 h. After cooling to room temperature, the reaction mixture was 
concentrated under reduced pressure and the resulting residue was purified by flash chromatography, 
eluting with (60:40) ethyl acetate/hexane, to give acid 3f (84.3 mg, 33%), as a white solid. 
20][ D = 
78.0 º (c1.0, CH3OH). Mp: 134.0134.5 ˚C
. 1
H NMR (300 MHz, CD3OD) δ: 7.09 (d, J = 8.0 Hz, 
2H, 2×ArH), 7.00 (d, J = 8.0 Hz, 2H, 2×ArH), 6.67 (m, 1H, H2), 4.47 (d, J = 11.8 Hz, 1H, OCHH), 
4.42 (d, J = 11.8 Hz, 1H, OCHH), 4.26 (m, 1H, H3), 3.72 (m, 2H, H4H5), 2.562.48 (m, 1H, H6ax), 
2.232.17 (m, 1H, H6eq) and 2.17 (s, 3H, CH3) ppm. 
13
C NMR (75 MHz, CD3OD) δ: 170.0 (C), 
139.2 (CH), 138.4 (C), 136.8 (C), 130.3 (C), 129.9 (2×CH), 128.9 (2×CH), 76.2 (CH), 72.4 (OCH2), 
70.8 (CH), 67.5 (CH), 28.4 (CH3) and 21.2 (CH2) ppm. IR (ATR) ʋ: 3460 (OH), 3371 (OH) and 
1688 (CO) cm
1
. MS (ESI) m/z = 277 (MH). HRMS calcd for C15H17O5 (MH): 277.1081; found, 
277.1081. 
General procedure for the synthesis of compounds 3  A solution of ester 10 (1 equivalent) in 
THF (0.1 M) was treated with an aqueous solution of lithium hydroxide (2.5 equivalents, 0.5 M). 
The resulting mixture was stirred at room temperature for 30 min and then MilliQ water was added. 
The organic solvent was removed under reduced pressure and the resulting aqueous solution was 
washed with diethyl ether (×3). The aqueous layer was treated with Amberlite IR-120 (H
+
) until pH 
6. The filtrate and the washings were lyophilized to give the acids 3. 
(3R,4R,5R)-5-benzyloxy-3,4-dihydroxycyclohex-1-ene-1-carboxylic acid (3a)  Ester 10a (34 mg, 
0.12 mmol), THF (1.2 mL) and LiOH (0.6 mL, 0.5 M). 3a (24 mg, 76%) as a white solid. 
20][ D = 
92.0° (c2.6, MeOH). Mp: 210.7–212.2 ºC. 
1
H NMR (300 MHz, CD3OD) δ: 7.24 (m, 5H, 5ArH), 
6.60 (m, 1H, H2), 4.61 (d, J = 12 Hz, 1H, OCHH), 4.55 (d, J = 12 Hz, 1H, OCHH), 4.30 (m, 1H, 
H3), 3.77 (m, 2H, H4H5), 2.68 (dd, J = 3.9 and 18 Hz, 1H, H6ax) and 2.26 (dd, J = 2.2 and 19.7 Hz, 
1H, H6eq) ppm. 
13
C NMR (75 MHz, CD3OD) δ: 172.6 (C), 140.1 (C), 135.9 (CH), 133.6 (C), 129.3 
(2CH), 128.9 (2CH), 128.6 (CH ), 76.5 (CH), 72.5 (OCH2), 71.8 (CH), 67.9 (CH) and 29.8 (CH2) 




MS (ESI): 263 (MH). HRMS calcd 
for C14H15O5 (MH): 263.0925; found, 263.0918. 
(3R,4R,5R)-3,4-dihydroxy-5-(3-methoxybenzyloxy)cyclohex-1-ene-1-carboxylic acid (3b)  Ester 
10a (27.6 mg, 0.09 mmol), THF (0.9 mL) and LiOH (0.46 mL, 0.5 M). 3b (20.7 mg, 78%), as a 
white solid.  20][ D = 83.3° (c1.8, MeOH). Mp: 130.3132.1 ºC. 
1
H NMR (300 MHz, CD3OD) δ: 
7.19 (t, J = 7.5 Hz, 1H, ArH), 6.89 (m, 2H, 2ArH), 6.78 (dd, J = 3.9 and 7.8 Hz, 1H, ArH), 6.63 (m, 
1H, H2), 4.62 (d, J = 12.3 Hz, 1H, OCHH), 4.56 (d, J = 12.0 Hz, 1H, OCHH), 4.33 (m, 1H, H3), 
3.79 (m, 2H, H4H5), 3.75 (s, 3H, OCH3), 2.70 (d, J = 17.7 Hz, 1H, H6ax) and 2.28 (dd, J = 3.9 and 
17.7 Hz, 1H, H6eq) ppm. 
13
C RMN (75 MHz, CD3OD) δ: 174.9 (C), 163.8 (C), 144.2 (2C), 138.6 
(CH), 132.8 (CH), 123.5 (CH), 116.7 (CH ), 116.6 (CH), 79.0 (CH), 74.9 (OCH2), 74.2 (CH), 70.3 





293 (MH). HRMS calcd for C15H17O6 (MH): 293.1031; found, 293.1027. 
(3R,4R,5R)-5-(3-fluorobenzyloxy)-3,4-dihydroxycyclohex-1-ene-1-carboxylic acid (3c)  Ester 
10c (38.1 mg, 0.13 mmol), THF (1.3 mL) and LiOH (0.66 mL, 0.5 M). 3c (24.8 mg, 68%), as a white 
solid. 
20][ D = 78.4° (c2.9, MeOH). Mp: 123.9124.4 ºC. 
1
H NMR (300 MHz, CD3OD) δ: 7.26 (dt, 
J = 6.9 and 9.0 Hz, 1H, 1ArH), 7.07 (m, 2H, 2ArH), 6.91 (dt, J = 2.7 and 10.5 Hz, 1H, 1ArH), 
6.66 (br s, 1H, H2), 4.62 (d, J = 15.0 Hz, 1H, OCHH), 4.56 (d, J = 15.0 Hz, 1H, OCHH), 4.31 (m, 
1H, H3), 3.78 (m, 2H, H4H5), 2.66 (m, 1H, H6ax) and 2.25 (m, 1H, H6eq) ppm. 
13
C NMR (75 MHz, 
CD3OD) δ: 171.4 (C), 164.4 (C, J = 291 Hz), 143.9 (C, J = 9 Hz), 137.4 (CH), 132.1 (C), 131.1 (CH, 
J = 10 Hz), 124.2 (CH, J = 3 Hz), 115.3 (CH, J = 3 Hz), 115.0 (CH, J = 1 Hz), 76.8 (CH), 71.7 (CH2), 
71.5 (CH), 67.7 (CH) and 29.3 (CH2) ppm. IR (ATR) ʋ: 3407 (OH), 3312 (OH) and 1686 (CO) cm
-1
. 
MS (ESI): 281 (MH). HRMS calcd for C14H14FO5 (MH): 281.0831; found, 281.0823. 
Sodium (3R,4R,5R)-3,4-dihydroxy-5-((3-nitrobenzyloxy)cyclohex-1-ene-1-carboxylate (3e)  A 
solution of ester 10e (30 mg, 0.09 mmol) in THF (0.9 mL) was treated with an aqueous solution of 
sodium hydroxide (0.19 mL, 0.5 M). The resulting mixture was stirred at room temperature for 30 
min and then MilliQ water was added. The organic solvent was removed under reduced pressure and 
the resulting aqueous solution was washed with diethyl ether (×2) and lyophilized to give the sodium 
salt 3e (28 mg, 98%), as a brown foam. 20][ D = 23.7º (c1.0, H2O). 
1
H NMR (300 MHz, D2O) δ: 
8.26 (br s, 1H, ArH), 8.18 (d, J = 7.6 Hz, 1H, ArH), 7.80 (d, J = 7.5 Hz, 1H, ArH), 7.60 (t, J = 7.9 
Hz, 1H, ArH), 6.43 (br s, 1H, H2), 4.81 (d, J = 10.3 Hz, 1H, OCHH), 4.73 (d, J = 10.3 Hz, 1H, 
OCHH), 4.42 (br s, 1H, H3), 3.91 (m, 2H, H5+H4), 2.83 (dd, J = 4.1 and 17.5 Hz, 1H, H6ax) and 
2.26 (dd, J = 5.3 and 17.5 Hz, 1H, H6eq) ppm. 
13
C NMR (125 MHz, D2O) δ: 175.1 (C), 147.8 (C), 
139.7 (C), 135.4 (C), 134.7 (CH), 130.8 (CH), 129.7 (CH), 123.0 (CH), 122.8 (CH), 75.4 (CH), 70.4 
(CH), 70.3 (OCH2), 66.3 (CH) and 30.0 (CH2) ppm. IR (ATR) ʋ: 3345 (OH), 1570 (CO) and 1531 
(NO) cm
-1
. MS (ESI) m/z = 332 (MNa
+
). HRMS calcd for C14H15NO7Na (MNa
+
): 332.0741; found, 
332.0741.  
Sodium (3R,4R,5R)-3,4-dihydroxy-5-((perfluorophenyl)methoxy)cyclohex-1-ene-1-carboxylate 
(3g)  A solution of ester 10g (38.0 mg, 0.10 mmol) in THF (1.0 mL) was treated with an aqueous 
solution of sodium hydroxide (0.2 mL, 0.10 mmol, 0.5 M). The resulting mixture was stirred at room 
temperature for 6 h and then MilliQ water was added. The organic solvent was removed under 
reduced pressure and the resulting aqueous solution was washed with diethyl ether (×3) and 
lyophilized to give the sodium salt 3e (38.5 mg, 99%), as a white solid. 20][ D = 71.4º (c1.0, H2O). 
Mp: 225.2 ºC (dec.). 
1
H NMR (500 MHz, D2O) δ: 6.43 (br s, 1H, H2), 4.88 (d, J = 12.0 Hz, 1H, 
OCHH), 4.86 (d, J = 12.0 Hz, 1H, OCHH), 4.39 (m, 1H, H3), 3.92 (m, 1H, H5), 3.84 (m, 1H, H4), 
2.64 (dd, J = 4.0 and 18.0 Hz, 1H, H6eq) and 2.23 (dd, J = 6.5 and 18.0 Hz, 1H, H6ax) ppm. 
13
C NMR 
(125 MHz, D2O) δ: 175.0 (C), 146.4136.3 (m, 5C), 135.4 (C), 130.6 (CH), 110.6 (t, JC-F= 10 Hz, 
C), 75.7 (CH), 70.2 (CH ), 66.2 (CH ), 58.5 (OCH2) and 30.0 (CH2) ppm. 
19
F NMR (282 MHz, D2O) 
δ: 143.8 (d, J = 16 Hz, 2F), 154.3 (t, J = 21 Hz, 1F) and 162.8 (dt, J = 6 and 21 Hz, 2F) ppm. IR 
(ATR) ʋ: 3371 (OH) and 1504 (CO) cm
-1
. IR (ATR) ʋ: 3371 (OH) and 1504 (CO) cm
-1
. MS (ESI) 
m/z = 353 (MNa). HRMS calcd for C14H10F5O5 (MNa): 353.0454; found, 353.0452. 
(3R,4R,5R)-3,4-dihydroxy-5-(naphthy-2-yl)methoxycyclohex-1-ene-1-carboxylic acid (3h)  
Ester 10h (47 mg, 0.14 mmol), THF (1.4 mL) and LiOH (0.70 mL, 0.5 M). 3h (19.6 mg, 45%), as a 
white solid. 
20][ D = 58.6° (c2.5, MeOH). Mp: 185.6187.1 ºC. 
1
H NMR (300 MHz, CD3OD) δ: 
7.82 (m, 4H, 4ArH), 7.47 (m, 3H, 3ArH), 6.74 (br s, 1H, H2), 4.83 (d, J = 12.0 Hz, 1H, OCHH), 
4.77 (d, J = 12.0 Hz, 1H, OCHH), 4.41 (m, 1H, H3), 3.90 (m, 2H, H4H5), 2.73 (br d, J = 18.3 Hz, 
1H, H6ax) and 2.37 (dd, J = 4.5 and 18.3 Hz, 1H, H6eq) ppm. 
13
C NMR (75 MHz, CD3OD) δ: 171.3 
(C), 137.8 (CH), 137.6 (C), 134.8 (C), 134.5 (C), 131.9 (C), 129.1 (CH), 128.9 (CH), 128.7 (CH), 
127.5 (CH ), 127.1 (CH ), 127.0 (CH), 126.9 (2CH), 76.6 (CH), 72.7 (CH2), 71.4 (CH), 67.7 (CH) 
and 29.2 (CH2) ppm. IR (ATR) ʋ: 3299 (OH) and 1686 (CO) cm
-1
. MS (ESI): 313 (MH). HRMS 
calcd for C18H17O5 (MH): 313.1081; found, 313.1092. 
(3R,4R,5R)-5-(benzo[b]thiophen-5-yl)methoxy-3,4-dihydroxycyclohex-1-ene-1-carboxylic acid 
(3i)  Ester 10i (83.5 mg, 0.25 mmol), THF (2.5 mL) and LiOH (1.25 mL, 0.5 M). 3i (43.3 mg, 
54%), as a white solid. Mp: 188.1188.8 ºC. 
20][ D = 77.7° (c0.6, MeOH). 
1
H NMR (300 MHz, 
CD3OD) δ: 7.80 (m, 2H, 2ArH), 7.50 (d, J = 5.1 Hz, 1H, ArH), 7.30 (d, J = 6.3 Hz, 2H, 2ArH), 
6.76 (br s, 1H, H2), 4.73 (d, J = 12.0 Hz, 1H, OCHH), 4.68 (d, J = 12.0 Hz, 1H, OCHH), 4.37 (br s, 
1H, H3), 3.85 (br s, 2H, H4H5), 2.64 (d, J = 18.0 Hz, 1H, CHH-6) and 2.32 (d, J = 18.0 Hz, 1H, 
CHH-6) ppm. 
13
C NMR (75 MHz, CD3OD) δ: 170.1 (C), 141.3 (C), 140.5 (C), 139.3 (CH), 136.2 
(C), 130.4 (C), 127.9 (CH), 125.5 (CH), 124.9 (CH), 123.9 (CH), 123.3 (CH), 76.4 (CH), 72.6 
(CH2), 71.0 (CH), 67.6 (CH) and 28.6 (CH2) ppm. IR (ATR) ʋ: 3396 (OH) and 1697 (CO) cm
-1
. MS 
(ESI): 319 (MH). HRMS calcd for C16H15O5S (MH): 319.0646; found, 319.0644.  
Methyl (3S,4R,5R)-3,4-dihydroxy-5-(mesyloxy)cyclohex-1-ene-1-carboxylate (12)  A solution of 
acetal 11
24
 (171 mg, 0.50 mmol) in dry dichloromethane (1.7 mL), under argon and at 0 ºC, was 
treated sucesively with dry trimethylamine (0.10 mL, 0.75 mmol) and mesyl chloride (50 µL, 0.60 
mmol) dropwise. The resulting solution was stirred at room temperature for 1 h. The reaction 
mixture was treated with aqueous solution of potassium carbonate (20%) and then diluted with 
dichloromethane. The organic layer was separated and the aqueous layer was extracted with 
dichloromethane (×2). The combined organic extracts were dried (anh. Na2SO4), filtered and 
concentrated under reduced pressure. The resulting residue was dissolved in a mixture of 
methanol/water/HCl (c) (7.9 mL, 100:1:0.1) was stirred at room temperature for 15 min. The reaction 
mixture was neutralized with saturated solution of sodium bicarbonate followed by powdered sodium 
bicarbonate and then diluted with ethyl acetate. The organic layer was separated and the aqueous 
layer was extracted with ethyl acetate (×2). The combined organic extracts were washed with water 
(×3), brine (×2) and dried (anh. Na2SO4). The resulted organic extract was concentrated under 
reduced pressure and purified by flash chromatography, eluting with (60:40) ethyl acetate/hexane to 
give mesylate 12 (229 mg, 87%), as a white solid. 
20][ D = 39.5º (c1.2, CH3OH). Mp: 144.0144.4 
ºC. 
1
H NMR (250 MHz, CD3OD)  6.82 (m, 1H, H2), 4.85 (m, 1H, H5), 4.36 (m, 1H, H3), 
3.893.83 (m, 1H, H4), 3.74 (s, 3H, OCH3), 3.13 (s, 3H, CH3), 2.992.89 (m, 1H, H6ax) and 
2.532.41 (m, 1H, H6eq) ppm. 
13
C NMR (63 MHz, CD3OD) 167.9 (C), 138.8 (CH), 129.4 (C), 
79.2 (CH), 70.3 (CH), 67.0 (CH), 52.6 (OCH3), 38.3 (CH3) and 30.1 (CH2) ppm. IR (ATR) ʋ: 3395 
and 3301 (OH) and 1711 (CO) cm
1
. MS (ESI) m/z = 289 (MNa
+
). HRMS calcd for C9H14O7SNa 
(MNa
+
): 289.0352; found, 289.0350. 
Epoxide 13. A solution of mesylate 12 (96 mg, 0.36 mmol) in dry methanol (0.5 mL) was treated 
with a solution of sodium methoxide (68 mg, 1.26 mmol) in dry methanol (0.55 mL). The resulting 
suspension was stirred at room temperature for 7 h. The solvent was concentrated under reduced 
pressure and the crude residue was dissolved in a mixture of dichloromethane and water. The organic 
layer was separated and the aqueous layer was extracted with dichloromethane (×2). The combined 
organic extracts were dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography, eluting with (40:60) ethyl acetate/hexane, to 
give epoxide 13
25
 (52 mg, 85%), as a colorless oil.  
Methyl (3R,4S,5R)-5-azido-3,4-dihydroxycyclohex-1-ene-1-carboxylate (14). A solution of the 
epoxide 13 (21.5 mg, 0.13 mmol) in acetic acid (0.12 mL) was treated with sodium azide (44.2 mg, 
0.68 mmol) in water (40 µL) and then heated at 40 ºC for 24 h. After cooling to room temperature, 
the reaction mixture was diluted with diethyl ether and water. The organic layer was separated and 
the aqueous layer was extracted with diethyl ether (×2). The combined organic extracts were washed 
with saturated NaHCO3, dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography, eluting with (60:40) ethyl acetate/hexane, to 
give the azide 14
23
 (23.5 mg, 85%), as a white solid. Mp: 102.8103.0 ˚C. 
20][ D = 167.0º (c1.1, 
CHCl3). 
1
H NMR (250 MHz, CDCl3) δ: 6.88 (m, 1H, H2), 4.44 (t, J = 4.2 Hz, 1H, H3), 3.86 (m, 1H, 
H5), 3.77 (s, 3H, OCH3), 3.70 (dd, J = 4.3 and 9.3 Hz, 1H, H4), 2.92 (dd, J = 5.4 and 17.9 Hz, 1H, 
H6ax) and 2.332.21 (m, 1H, H6eq) ppm. 
13
C NMR (63 MHz, CDCl3) δ: 166.3 (C), 135.8 (CH), 
130.3 (C), 71.2 (CH), 65.5 (CH), 58.2 (OCH3), 52.3 (CH) and 28.9 (CH2) ppm. IR (ATR) ʋ: 3295 




carboxylate (15) – To a suspension of azide 14 (100 mg, 0.47 mmol) and 3-phenyl-1-propine (0.06 
mL, 0.47 mmol) in a 1:1 mixture of t-BuOH-water (1.5 mL) freshly prepared aqueous sodium 
ascorbate solution (0.47 mL, 1.0 M), followed by aqueous copper(II) sulphate solution (1.5 mL, 0.32 
M) were added. The resultant heterogenous mixture was stirred vigorously during 16 h and then 
diluted with water and ethyl acetate. The organic layer was separated and the aqueous phase was 
extracted with ethyl acetate (×2). All the combined organic extracts were dried (anh. Na2SO4), 
filtered and evaporated. The obtained residue was purified by flash chromatography, eluting with 
(50:50) ethyl acetate/hexane, to afford triazol 15 (99.4 mg, 64%), as a white solid. 20][ D = 87.1º 
(c1.1, MeOH). Mp: 153.8−154.5 ˚C. 
1
H NMR (300 MHz, CD3OD) δ: 7.77 (br s, 1H, ArH), 7.27 (m, 
4H, 4×ArH), 7.21 (m, 1H, ArH), 6.96 (br d, J = 3.0 Hz, 1H, H2), 4.81 (m, 1H, H5), 4.34 (t, J = 4.1 
Hz, 1H, H3), 4.11 (d, J = 4.0 Hz, 1H, H4), 4.06 (s, 2H, OCH2), 3.76 (s, 3H, OCH3), 3.03 (dd, J = 5.8 
and 17.9 Hz 1H, H6ax) and 2.90 (dd, J = 9.8 and 17.9 Hz, 1H, H6eq) ppm. 
13
C NMR (75 MHz, 
CD3OD) δ: 167.8 (C), 140.4 (C), 137.9 (CH), 131.1 (C), 129.6 (2×CH), 129.6 (2×CH), 127.4 (CH), 
124.2 (CH), 72.1 (CH), 67.0 (CH), 59.2 (OCH3), 52.6 (CH), 32.6 (OCH2) and 32.3 (CH2) ppm. IR 
(ATR) ʋ: 3237 (OH) and 1716 (CO) cm
-1
. MS (ESI) m/z = 330 (MH
+
). HRMS calcd for C17H20N3O4 
(MH
+
): 330.1448; found, 330.1448. 
(3R,4S,5R)-5-(4-benzyl-1H-1,2,3-triazol-1-yl)-3,4-dihydroxycyclohex-1-ene-1-carboxylic acid 
(4)  A solution of ester 15 (88.3 mg, 0.27 mmol) in THF (2.7 mL) was treated with an aqueous 
solution of lithium hydroxide (0.54 mL, 0.27 mmol, 0.5 M). The resulting mixture was stirred at 
room temperature for 30 min and then MilliQ water was added. The organic solvent was removed 
under reduced pressure and the resulting aqueous solution was washed with diethyl ether (×3). The 
aqueous layer was treated with Amberlite IR-120 (H
+
) until pH 6. The filtrate and the washings were 
lyophilized to give the acid 4 (81.9 mg, 97%), as a white foam. 20][ D = 77.7º (c1.3, MeOH). Mp: 
152.0153.5 ºC. 
1
H NMR (500 MHz, CD3OD) δ: 7.55 (br s, 1H, ArH), 7.22 (m, 4H, 4×ArH), 7.15 
(m, 1H, ArH), 6.84 (br s, 1H, H2), 4.75 (m, 1H, H5), 4.28 (m, 1H, H3), 4.03 (d, J = 11.3 Hz, 1H, 
H4), 4.01 (s, 2H, OCH2), 2.97 (dd, J = 4.5 and 17.7 Hz 1H, H6ax) and 2.90 (dd, J = 10.2 and 17.7 Hz, 
1H, H6eq) ppm. 
13
C NMR (125 MHz, CD3OD) δ: 168.4 (C), 139.0 (C), 134.9 (CH), 128.3 (CH), 
128.2 (3×CH), 126.1 (2×CH), 123.1 (C), 124.2 (CH), 72.1 (CH), 67.0 (CH), 59.2 (OCH3), 52.6 
(CH), 32.6 (CH2) and 32.3 (CH2) ppm. IR (ATR) ʋ: 3300 (OH) and 1710 (CO) cm
-1
. MS (ESI) m/z = 
314 (MH). HRMS calcd for C16H16N3O4 (MH): 314.1146; found, 314.1137. 
Methyl (3R,4S,5R)-5-(4-phenoxymethyl-1H-1,2,3-triazol-1-yl)-3,4-dihydroxycyclohex-1-ene-1-
carboxylate (16)  To a suspension of azide 14 (100 mg, 0.47 mmol) and 3-phenoxy-1-propine 
(0.06 mL, 0.47 mmol) in a 1:1 mixture of t-BuOH-water (2.4 mL) freshly prepared aqueous sodium 
ascorbate solution (0.47 mL, 1.0 M), followed by aqueous copper(II) sulphate solution (1.5 mL, 0.32 
M) were added. The resultant heterogenous mixture was stirred vigorously during 16 h and then 
diluted with water and ethyl acetate. The organic layer was separated and the aqueous phase was 
extracted with ethyl acetate (×2). All the combined organic extracts were dried (anh. Na2SO4), 
filtered and evaporated. The obtained residue was purified by flash chromatography, eluting with 
(50:50) ethyl acetate/hexane, to afford triazol 16 (129 mg, 79%), as a white foam. 20][ D = 41.9º 
(c1.3, MeOH). 
1
H NMR (300 MHz, CD3OD) δ: 7.83 (s, 1H, ArH), 6.98 (t, J = 8.0 Hz, 2H, 2×ArH), 
6.66 (m, 3H, 3×ArH), 6.63 (s, 1H, H2), 4.59 (m, 1H, H5), 4.55 (s, 2H, OCH2), 4.06 (t, J = 4.3 Hz, 
1H, H3), 3.81 (dd, J = 4.1 and 10.8 Hz, 1H, H4), 3.46 (s, 3H, OCH3), 2.75 (dd, J = 5.9 and 17.9 Hz 
1H, H6eq) and 2.63 (dd, J = 10.1 and 17.9 Hz, 1H, H6ax) ppm. 
13
C NMR (75 MHz, CD3OD) δ: 167.8 
(C), 159.8 (C), 144.5 (C), 137.9 (CH), 131.1 (C), 130.5 (2×CH), 125.7 (CH), 122.2 (CH), 115.8 
(2×CH), 72.1 (CH), 66.7 (CH), 62.4 (OCH2), 59.4 (CH), 52.6 (OCH3) and 32.3 (CH2) ppm. IR 
(ATR) ʋ: 3313 (OH) and 1722 (CO) cm
-1
. MS (ESI) m/z = 346 (MH
+
). HRMS calcd for C17H20N3O5 
(MH
+
): 346.1397; found, 346.1398. 
(3R,4S,5R)-5-(4-phenoxymethyl-1H-1,2,3-triazol-1-yl)-3,4-dihydroxycyclohex-1-ene-1-
carboxylic acid (5)  A solution of ester 16 (112.7 mg, 0.33 mmol) in THF (3.3 mL) was treated 
with an aqueous solution of lithium hydroxide (0.66 mL, 0.33 mmol, 0.5 M). The resulting mixture 
was stirred at room temperature for 30 min and then MilliQ water was added. The organic solvent 
was removed under reduced pressure and the resulting aqueous solution was washed with diethyl 
ether (×3). The aqueous layer was treated with Amberlite IR-120 (H
+
) until pH 6. The filtrate and the 
washings were lyophilized to give the acid 5 (104 mg, 95%), as a white foam. 20][ D = 77.2º (c1.1, 
MeOH). 
1
H NMR (500 MHz, CD3OD) δ: 7.98 (s, 1H, ArH), 7.12 (t, J = 7.5 Hz, 2H, 2×ArH), 6.85 
(d, J = 8.0 Hz, 2H, 2×ArH), 6.79 (t, J = 7.4 Hz, 1H, ArH), 6.64 (m, 1H, H2), 5.00 (s, 2H, OCH2), 
4.72 (dt, J = 5.8 and 10.8 Hz, 1H, H5), 4.20 (t, J = 4.6 Hz, 1H, H3), 3.97 (dd, J = 4.2 and 10.9 Hz, 
1H, H4), 2.92 (dd, J = 5.7 and 17.9 Hz 1H, H6eq) and 2.76 (ddd, J = 1.6, 10.6 and 17.9 Hz, 1H, H6ax) 
ppm. 
13
C NMR (75 MHz, CD3OD) δ: 171.3 (C), 158.4 (C), 143.1 (C), 134.6 (C), 132.3 (CH), 129.2 
(2×CH), 124.2 (CH), 120.9 (CH), 114.5 (2×CH), 71.2 (CH), 66.1 (CH), 61.0 (OCH2), 58.6 (CH) and 
32.4 (CH2) ppm. IR (ATR) ʋ: 3407 (OH) and 1677 (CO) cm
-1
. MS (ESI) m/z = 330 (MH). HRMS 
calcd for C16H16N3O5 (MH): 330.1095; found, 330.1090.  
Methyl (3S,4S,5R)-3-amino-4-hydroxy-5-(naphth-2-yl)metoxycyclohex-1-ene-carboxylate (17h). 
A solution of alcohol 10h (128 mg, 0.39 mmol) in dry tetrahydrofuran (3.5 mL), under inert 
atomosphere and at 0 ºC, was treated with triphenylphosphine (156 mg, 0.50 mmol), previously 
prepared hydrazoic acid
28
 (0.45 mL, 0.59 mmol) and DIAD (0.12 mL, 0.59 mmol). The resulting 
solution was stirred at 0 ºC for 1.5 h and then the solvent was removed under reduced pressure. The 
resulting residue was purified by flash chromatography, eluting with (25:75) ethyl acetate/hexane. A 
solution of the resulting yellow oil (94 mg) in tetrahydrofuran (27 mL) and water (0.07 mL) was 
treated with triphenylphosphine (79.5 mg, 0.30 mmol) and then heated under reflux for 4 h. After 
cooling to room temperature, the solvent was removed under reduced pressure and the resulting 
residue was purified by flash chromatography, eluting with (10:90) methanol/dichlorometane, to give 
the amine 17h (64 mg, 70%), as a yellow oil. 
20][ D = –49.3º (c1.1, CHCl3). 
1
H NMR (300 MHz, 
CDCl3) δ: 7.82 (m, 4H, 4×ArH), 7.47 (d, J = 9.0 Hz, 3H, 3×ArH), 6.66 (br s, 1H, H2), 4.88 (d, J = 
11.6 Hz, 3H, OCHH), 4.67 (d, J = 11.6 Hz, 3H, OCHH), 3.74 (s, 3H, OCH3), 3.56 (m, 1H, H5), 3.43 
(d, J = 5.8 Hz, 2H, H3+H4), 3.00 (dd, J = 5.4 and 17.3 Hz, 1H, H6ax), 2.35 (br s, 3H, OH+NH2) and 
2.28–2.15 (m, 1H, H6eq) ppm.
 13
C NMR (100 MHz, CDCl3) δ: 166.8 (C), 140.4 (CH), 135.4 (C), 
133.3 (C), 133.1 (C), 128.5 (CH), 127.9 (CH), 127.8 (CH), 127.4 (C), 126.8 (CH), 126.3 (CH), 126.1 
(CH), 125.9 (CH), 77.0 (2×CH), 71.5 (OCH2), 54.4 (CH), 52.1 (OCH3) and 29.8 (CH3) ppm. IR 
(ATR) ʋ: 3313 (NH), 3281 (OH) and 1716 (CO) cm
–1
. MS (ESI) m/z = 328 (MH
+
). HRMS calcd for 
C19H22NO4 (MH
+
): 328.1543; found, 328.1547. 
Sodium (3S,4S,5R)-3-amino-4-hydroxy-5-(naphth-2-yl)metoxycyclohex-1-ene-carboxylate (6h). 
A solution of ester 17h (58 mg, 0.18 mmol) in THF (1.8 mL) was treated with an aqueous solution of 
sodium hydroxide (0.36 mL, 0.5 M). The resulting mixture was stirred at room temperature for 30 
min and then MilliQ water was added. The organic solvent was removed under reduced pressure and 
the resulting aqueous solution was washed with diethyl ether (×2) and lyophilized to give the sodium 
salt 6h (54 mg, 93%), as a yellow foam. 
20][ D = –14.5º (c0.9, H2O). 
1
H NMR (500 MHz, D2O) δ: 
7.88 (m, 3H, 3×ArH), 7.85 (br s, 1H, ArH), 7.51 (m, 3H, 3×ArH), 6.17 (br s, 1H, H2), 4.78 (d, J = 
11.7 Hz, 1H, OCHH), 4.71 (d, J = 11.7 Hz, 1H, OCHH), 3.57 (td, J = 5.8 and 9.5 Hz, 1H, H5), 3.40 
(t, J = 8.9 Hz, 1H, H4), 3.28 (m, 1H, H3), 2.80 (dd, J = 5.7 and 17.2 Hz, 1H, H6ax) and 2.18–2.11 
(m, 1H, H6eq) ppm. 
13
C NMR (125 MHz, D2O) δ: 175.2 (C), 135.3 (C), 133.7 (CH), 132.8 (2×C), 
132.7 (C), 128.2 (CH), 127.8 (CH), 127.6 (CH), 127.1 (CH), 126.5 (CH), 126.4 (2×CH), 77.3 (CH), 
76.2 (CH), 71.5 (OCH2), 55.5 (CH) and 31.0 (CH2) ppm. IR (ATR) ʋ: 3326 (NH+OH) and 1551 
(CO) cm
-1
. MS (ESI) m/z = 336 (MH
+
). HRMS calcd for C18H19NNaO4 (MH
+
): 336.1206; found, 
336.1199. 
Methyl (3S,4S,5R)-3-amino-5-(benzo[b]thiophen-5-yl)methoxy-4-hydroxycyclohex-1-ene-
carboxylate (17i). A solution of alcohol 10i (124.5 mg, 0.37 mmol) in dry tetrahydrofuran (3.4 mL), 
under inert atomosphere and at 0 ºC, was treated with triphenylphosphine (148.4 mg, 0.56 mmol), 
previously prepared hydrazoic acid (0.43 mL, 0.56 mmol) and DIAD (0.11 mL, 0.56 mmol). The 
resulting solution was stirred at 0 ºC for 1.5 h and then the solvent was removed under reduced 
pressure. The resulting residue was purified by flash chromatography, eluting with (25:75) ethyl 
acetate/hexane. A solution of the resulting yellow oil (107 mg) in tetrahydrofuran (30 mL) and water 
(0.07 mL) was treated with triphenylphosphine (87 mg, 0.33 mmol) and then heated under reflux for 
4 h. After cooling to room temperature, the solvent was removed under reduced pressure and the 
resulting residue was purified by flash chromatography, eluting with (10:90) 
methanol/dichlorometane, to give the amine 10i (71.8 mg, 70%), as a yellow oil. 
20][ D = –47.4º 
(c1.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.82 (d, J = 8.2 Hz, 1H, ArH), 7.76 (br s, 1H, ArH), 
7.42 (d, J = 4.7 Hz, 1H, ArH), 7.29 (m, 2H, 2×ArH), 6.63 (br s, 1H, H2), 4.81 (d, J = 11.3 Hz, 1H, 
OCHH), 4.60 (d, J = 11.3 Hz, 1H, OCHH), 3.72 (s, 3H, OCH3), 3.51 (m, 1H, H5), 3.38 (br s, 2H, 
H3+H4), 2.95 (dd, J = 5.3 and 17.3 Hz, 1H, H6ax), 2.44 (br s, 3H, OH+NH2) and 2.19 (m, 1H, H6eq) 
ppm. 
13
C NMR (63 MHz, CDCl3) δ: 166.7 (C), 140.3 (CH), 139.7 (C), 139.3 (C), 134.1 (CH), 127.3 
(2×C), 127.3 (CH), 124.4 (CH), 123.8 (CH), 123.0 (CH), 122.6 (CH), 76.9 (CH), 76.6 (CH), 71.4 
(OCH2), 54.2 (CH), 52.0 (OCH3) and 29.8 (CH2) ppm. IR (ATR) ʋ: 3065 (NH+OH) and 1716 (CO) 
cm
–1
. MS (ESI) m/z = 334 (MH
+
). HRMS calcd for C17H20NSO4 (MH
+
): 334.1108; found, 334.1113. 
Sodium (3S,4R,5R)-3-amino-5-(benzo[b]thiophen-5-yl)methoxy-4-hydroxycyclohex-1-ene-
carboxylate (6i). A solution of ester 17i (68.1 mg, 0.18 mmol) in THF (2 mL) was treated with an 
aqueous solution of sodium hydroxide (0.4 mL, 0.5 M). The resulting mixture was stirred at room 
temperature for 30 min and then MilliQ water was added. The organic solvent was removed under 
reduced pressure and the resulting aqueous solution was washed with diethyl ether (×2) and 
lyophilized to give the sodium salt 6i (62 mg, 91%), as a yellow foam. 
20][ D = –19.6º (c1.0, H2O). 
1
H 
NMR (500 MHz, D2O) δ: 7.60 (d, J = 8.1 Hz, 1H, ArH), 7.53 (br s, 1H, ArH), 7.28 (d, J = 4.8 Hz, 
1H, ArH), 7.11 (m, 1H, ArH), 6.13 (br s, 1H, H2), 4.46 (d, J = 11.5 Hz, 1H, OCHH), 4.38 (d, J = 
11.5 Hz, 1H, OCHH), 3.27 (br s, 2H, H5+H4), 3.11 (br s, 1H, H3), 2.67 (d, J = 15.9 Hz, 1H, H6ax) 
and 2.06 (m, 1H, H6eq) ppm. 
13
C NMR (125 MHz, D2O) δ: 174.9 (C), 139.5 (C), 138.9 (C), 133.8 
(CH+C), 132.8 (C), 127.4 (CH), 124.6 (CH), 123.9 (CH), 123.2 (CH), 122.5 (CH), 77.1 (CH), 76.1 
(CH), 71.3 (OCH2), 53.4 (CH) and 31.0 (CH2) ppm. IR (ATR) ʋ: 3332 (NH+OH) and 1551 (CO) 
cm
1
. MS (ESI) m/z = 342 (MH
+
). HRMS calcd for C16H17NSNaO4 (MH
+
): 342.0770; found, 
342.0769. 
Shikimate kinase assay  Both enzymes were purified as described previously.
30,18 
The H. pylori 
enzyme used in these studies was expressed and produced using genomic DNA from an isolated 
clinical strain, courtesy of Guadalajara Hospital (Guadalajara, Spain). Concentrated solutions of Hp-
SK (7.4 mg mL
–1
) or Mt-SK (1.5 mg mL
–1
) were stored in potassium phosphate buffer (50 mM, pH 
7.2), DTT (1 mM) and NaCl (150 mM). When required for assays, aliquots of the enzyme stock 
solutions were diluted in water and buffer and stored on ice.
 
Enzyme activity was measured by 





 6 220) in a coupled assay format wherein ADP formed after the formation of 
shikimate-3-phosphate (2) was detected using pyruvate kinase (PK) and lactate dehydrogenase 
(LDH). Oxidation of NADH to NAD during PK-LDH activity was monitored at 340 nm. Standard 
assay conditions for shikimate kinase were 100 mM Tris.HCl pH 7.7, 100 mM NaCl, 5 mM MgCl2, 
2.5 mM ATP, 1 mM shikimic acid (1), 0.20 mM NADH, 2.8 units of PK-LDH and 0.03 unit of SK 
protein. One unit of enzyme is defined as the amount of enzyme required to convert 1 µmol of 





 15 400) and NADH were calibrated by measuring the absorbance at 259 nm and 
340 nm in the UV spectrum, respectively. Solutions of shikimic acid (1) were calibrated by 
equilibration with SK and measurement of the change in the UV absorbance at 340 nm due to the 
disappearance of NADH.
 
The Ki values of compounds 36 against SK were obtained from Dixon 
plots (1/v vs [I]) of assay data. The initial rates at fixed enzyme and substrate concentrations (0.25–
1.4 Km) were measured in the absence and in the presence of various inhibitor concentrations. The 










Susceptibility testing  A H. pylori clinical isolate obtained from a biopsy of a patient of the 
Guadalajara Hospital (Guadalajara, Spain) was employed. The clinical strain was cultured on plates 
of Trypticase soy agar with 10% sheep blood and was incubated under microaerophilic conditions 
(5% O2, 10% CO2, 85% N2) for 56 days. The strain was stored at 80°C in Luria-Bertani medium 
with 20% of glicerol until use. The agar dilution method was used to determine the Minimum 
Inhibitory Concentration (MICs) of the compounds, according to the standard method recommended 
by CLSI.
27
 The suspension turbidity used to inoculate the plates was adjusted to a McFarland opacity 
standard of 2.0. Then 10 µL of the bacterial suspension were dropped in plates of Trypticase soy agar 
with 10% sheep blood. The plates contained 2-fold dilutions of each compound with concentrations 
ranging from 4 to 1028 µg/mL. The MICs were determined after 6 days of incubation at 37°C under 
microaerophilic conditions. MIC values were defined as the lowest concentration of each compound 
that completely inhibited visible growth on plates. MIC assays were performed at least three times. 
Docking studies  These studies were carried out using the GOLD 5.2
20
 program and the enzyme 
coordinates collected in the MD simulation studies carried out with the SK complex containing: (a) 
Mt-SK/ATP/Mg
+2
/(6R)-6-hydroxyshikimic acid (10 ns)
18
; (b) Hp-SK/ADP/2 (50 ns). Different 
snapshots of the simulation were selected, specifically, those ones in which a large movement in the 
α-helices α2 and α3 of the SB domain was observed. Experimental details of the MD simulation 
studies are described in the next section. The best results were obtained after 7 ns of MD for Mt-SK 
and 11 ns for Hp-SK. Water molecules were removed from the model. Ligand geometries were 
minimized using the AM1 Hamiltonian as implemented in the program Gaussian 09
31 
and these were 
used as MOL2 files. Each ligand was docked in 25 independent genetic algorithm (GA) runs, and for 
each of these a maximum number of 100000 GA operations were performed on a single population 
of 50 individuals. Operator weights for crossover, mutation and migration in the entry box were used 
as default parameters (95, 95, and 10, respectively) along with the hydrogen bonding (4.0 Å) and van 
der Waals (2.5 Å) parameters. The position of (6R)-6-hydroxyshikimic acid and 2 in the 
corresponding model was used to define the active-site and the radius was set to 7 Å. The “flip ring 
corners” flag was switched on, while all the other flags were off. The GOLD scoring function was 
used to rank the ligands in order of fitness. 
Molecular dynamics simulations  Ligand minimization. Ligand geometries were minimized using 
a restricted Hartree–Fock (RHF) method and a 6–31G(d) basis set, as implemented in the ab initio 
program Gaussian 09. The resulting wavefunctions were used to calculate electrostatic potential-
derived (ESP) charges employing the restrained electrostatic potential (RESP)
21
 methodology, as 
implemented in the assisted model building with energy refinement (AMBER)
32 
suite of programs. 
The missing bonded and non-bonded parameters were assigned, by analogy or through interpolation, 
from those already present in the AMBER database (GAFF).
31,33 
Generation and minimization of ternary complexes. Simulations of (6R)-6-hydroxyshikimic 
acid/ATP/SK complex were carried out as previously described MD simulation of the Michaelis 
complex Mt-SK/ATP/1
18
 after manual replacement of shikimic acid (1) by (6R)-6-hydroxyshikimic 
acid. Simulations of Hp-SK/ADP/2 complex were performed using the enzyme geometries found in 
the crystal structure of Hp-SK in complex with ADP and 2 (PDB code 3MUF
19
). Simulations of 
inhibitor/ATP/SK complexes were carried out using the highest score solution obtained by docking 
and the enzyme geometries used in those docking studies, as described above. Computation of the 





of hydrogen and molecular mechanics parameters from the ff03 and GAFF force fields, respectively, 





 parameters used with the AMBER force field were included.
36,37
  
All systems were minimized in four stages: (a) initial minimization of the ligand and the closest 
residues of the SB domain (500 steps, first half using steepest descent and the rest using conjugate 
gradient); (b) minimization of the solvent and ions (5000 steps, first half using steepest descent and 
the rest using conjugate gradient); (c) minimization of the side chains, waters and ions (5000 steps, 
first half using steepest descent and the rest using conjugate gradient); (d) final minimization of the 
whole system (5000 steps, first half using steepest descent and the rest using conjugate gradient). A 




 was applied to those unminimized atoms during the 
first three stages (ac). The complex was immersed in a truncated octahedron of 5200 TIP3P water 
molecules and neutralized by addition of chloride (Mt-SK) or sodium (Hp-SK) ions.
32,38,39
 
Simulations. MD simulations were performed using the sander module from the AMBER 12 suite of 
programs. Periodic boundary conditions were applied and electrostatic interactions were treated 
using the smooth particle mesh Ewald method (PME)
40 
with a grid spacing of 1 Å. The cutoff 
distance for the non-bonded interactions was 9 Å. The SHAKE algorithm
41
 was applied to all bonds 
containing hydrogen, using a tolerance of 10
5
 Å and an integration step of 2.0 fs. Minimization was 
carried out in three steps, starting with the octahedron water hydrogens, followed by solvent 
molecules and counterions, and finally the entire system. The minimized system was then heated at 
300 K at 1 atm by increasing the temperature from 0 K to 300 K over 100 ps and by keeping the 




 was applied to all  
carbons during the heating stage. Finally, an equilibration of the system at constant volume (100 ps 




 to  alpha carbons) and constant pressure (another 100 




 to  alpha carbons) were performed. The positional 




(5 steps, 100 ps each), and the resulting 
systems were allowed to equilibrate further (100 ps). Unrestrained MD simulations were carried out 
for 50 ns. System coordinates were collected every 10 ps for further analysis.
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Figure 1. Selected examples of SK inhibitors identified by screening
13,14
 and by structure-based
18
 
desing. The reported IC50 and Ki values for Mt-SK and Hp-SK are included. 
  





Figure 2. Target compounds 36.  
  
 
Figure 3. Comparison of the complexes Hp-SK/ADP/2 (PDB entry 3MUF, 2.3 Å, gray) vs E114A 
Hp-SK/7 (PDB entry 3N2E, 2.53 Å, green). Note the large conformational change of the LID 




Figure 4. (A) Overall view of the Mt-SK motion required for product release from the active site 
obtained by MD simulations. (B) Detail of the large conformational changes of the LID and the -
helices 2, 3 and 5 of the SB domains during 10 ns of simulation. The arrangement of the most 
open/closed conformations of the LID and SB domains are shown. (C) Conformational changes of 
the LID and SB domains of Mt-SK caused by the binding mode of (6R)-6-hydroxyshikimic acid 
obtained by MD simulations. Comparison of the arrangement of those domains after minimization 
and prior simulation (blue) and after 7 ns of simulation (yellow) is shown. (D) Detail of the binding 
mode of (6R)-6-hydroxyshikimic acid in the active site of Mt-SK after 7 ns of simulation. The 
enzyme geometries found in this complex were used for docking studies. Relevant side chain 
residues are shown and labeled. Significant changes were not observed in the ADP/ATP binding site.  
 
 
Figure 5. Representative snapshots of product release from the active site of Hp-SK obtained by MD 
simulations. The large conformational changes of the LID and the -helices 3, 2 and 5 of the SB 
binding domains during 50 ns of simulation are highlighted. Significant changes were not observed 
in the ADP binding site. (A) Overall view of the enzyme motion. Superposition of shapshots C–I. 
(B) Detail of the largest conformational changes observed of the LID and -helices 3, 2 and 5. 
(C) After 10 ns. (D) After 23 ns. (E) After 25 ns. (F) After 28 ns. (G) After 32 ns. (H) After 50 ns. 
Relevant side chain residues are shown and labeled. 
  
 
Figure 6. Detail of the apolar pocket in the SB binding domain of Mt-SK (A) and Hp-SK (B) 
enzymes. The substrate (cyan) and relevant side chain residues are shown and labeled. 
  




Reagents and conditions: (a) RCH2Br, NaI, DIPEA, 150 ºC. (b) HCl (6 M), EtOH, 60 ºC. (c) 1. 
LiOH, THF, RT. 2. Amberlite IR-120 (H
+
). (d) NaOH, THF, RT. Compounds 3f and 3d were 
obtained directly by acid hydrolysis (b) of 9f and 9d, respectively. 
  





Reagents and conditions: (a) 1. MsCl, Et3N, DCM, 0 ºC to RT. 2. MeOH/H2O/HCl (100:1:0.1), RT. 
(b) NaOMe, MeOH, RT. (c) NaN3, AcOH, 40 ºC. (d) HCCCH2R, sodium ascorbate, tBuOH/H2O, 









Reagents and conditions: (a) 1. HN3, DIAD, PPh3, THF, 0 °C. 2. PPh3, H2O, THF, Δ. (b) NaOH, 
THF, RT.  
Table 1. Ki (µM) of compounds 36 against SK from M. tuberculosis and H. pylori
a
 








360  14 3.00  0.10 
2 3b 
 
135  5 1.00  0.05 
3 3c 
 
180  5 1.28  0.03 
4 3d 
 
109  5 2.10  0.15 
5 3e 
 
10  1 0.46  0.02 
6 3f 
 
166  16 10.9  0.6 
7 3g 
 
710  50 41  4 
8 3h 
 
22  1 1.80  0.10 
9  3i 
 





> 2000 95  4 
11 5 
 





> 2000 > 800 
13 6i 
 
415  21 535  10 
a
Assay conditions: Tris.HCl (100 mM, pH 7.7), ATP (2.5 mM), NADH (0.2 mM), PEP (1 
mM), MgCl2 (5 mM), KCl (0.1 M), lactate dehydrogenase (2 units), pyruvate kinase (2.8 
units), 25 ºC. 
b
Km (1) = 544 µM. 
c




Table 2. The minimum inhibitory concentration (MIC) of methyl esters 10e10i, 1516, 17h-i 















Figure 7. Binding mode of O-benzyl derivatives 3e, 3b and 3i obtained by docking and MD 
simulation studies in the active site of the SK enzymes. (A) 3e (yellow) in the active site of Mt-SK 
(wheat). (B) 3e (yellow) in the active site of Hp-SK (gray). (C) 3b (green) in the active site of Hp-
SK. (G) 3i (blue) in the active site of Hp-SK. (D,E,F,H) Comformational changes in the LID and SB 
domains of the SK enzymes caused by the binding of compounds 3e, 3b and 3i. The closed active 
form [PDB codes 2IYQ (Mt-SK, D) and 3MUF (Hp-SK, E-F and H)] and the inactive arrangement 
of the SK enzymes are compared for each ligand (spheres). (I) Comparison of the binding mode of 
compounds 3e, 3b and 3i in the active site of Hp-SK. The arrows highlight the most relevant changes 
in the LID and SB domains. Relevant side chain residues are shown and labeled. Polar (red) and 
lipophilic (magenta) interactions between ligands and enzyme residues are shown.  
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